

WEBVTT

NOTE duration:"01:07:56.331000"

NOTE language:en-us

NOTE Confidence: 0.8228898

00:00:00.000 --> 00:00:02.968 So today's will be the second part

NOTE Confidence: 0.8228898

00:00:02.968 --> 00:00:06.125 of our series about updates from

NOTE Confidence: 0.8228898

00:00:06.125 --> 00:00:09.110 the American Society of Hematology,

NOTE Confidence: 0.8228898

00:00:09.110 --> 00:00:11.565 with the highlights today focusing

NOTE Confidence: 0.8228898

00:00:11.565 --> 00:00:13.038 on lymphoid malignancy's.

NOTE Confidence: 0.8538571

00:00:15.300 --> 00:00:16.632 As you probably know,

NOTE Confidence: 0.8538571

00:00:16.632 --> 00:00:19.130 we have six sessions within this series.

NOTE Confidence: 0.8538571

00:00:19.130 --> 00:00:20.942 We had the myeloma session last

NOTE Confidence: 0.8538571

00:00:20.942 --> 00:00:23.388 week and this is actually has been

NOTE Confidence: 0.8538571

00:00:23.388 --> 00:00:25.734 recorded and available on the website.

NOTE Confidence: 0.8538571

00:00:25.740 --> 00:00:28.516 For those who could not attend last week,

NOTE Confidence: 0.8538571

00:00:28.520 --> 00:00:31.136 so feel free to check their website and

NOTE Confidence: 0.8538571

00:00:31.136 --> 00:00:33.806 we will also be including the slides

NOTE Confidence: 0.8538571

00:00:33.806 --> 00:00:36.454 for your own reference next week on

NOTE Confidence: 0.8538571

00:00:36.454 --> 00:00:38.958 January 29th will be the update on my

NOTE Confidence: 0.8538571

00:00:38.960 --> 00:00:40.790 load malignancy's February 5th will

NOTE Confidence: 0.8538571

00:00:40.790 --> 00:00:43.076 be pediatric leukemia and acute for

NOTE Confidence: 0.8538571

00:00:43.076 --> 00:00:45.076 plastic leukemia and pediatric oncology.

NOTE Confidence: 0.8538571

00:00:45.080 --> 00:00:47.719 February 12 will be the classical or

NOTE Confidence: 0.8538571

00:00:47.719 --> 00:00:50.213 benign hematology and February 19 will

NOTE Confidence: 0.8538571

00:00:50.213 --> 00:00:52.368 be cell therapy and transplantation.

NOTE Confidence: 0.8538571

00:00:52.370 --> 00:00:54.750 All of those are on Fridays and

NOTE Confidence: 0.8538571

00:00:54.750 --> 00:00:56.250 at 12:00 PM noon.

NOTE Confidence: 0.8736119

00:00:58.860 --> 00:01:01.317 All of those sessions will be recorded

NOTE Confidence: 0.8736119

00:01:01.317 --> 00:01:04.105 and the slides will be available along

NOTE Confidence: 0.8736119

00:01:04.105 --> 00:01:06.607 with the recordings after the sessions.

NOTE Confidence: 0.8736119

00:01:06.610 --> 00:01:09.733 There will be CME credit for those who submit

NOTE Confidence: 0.8736119

00:01:09.733 --> 00:01:12.637 for it at the end of the entire series,

NOTE Confidence: 0.8736119

00:01:12.640 --> 00:01:15.034 and they'll be a form for feedback

NOTE Confidence: 0.8736119

00:01:15.034 --> 00:01:17.414 where we would love to get your
NOTE Confidence: 0.8736119

00:01:17.414 --> 00:01:19.738 input about what you like and what
NOTE Confidence: 0.8736119

00:01:19.738 --> 00:01:22.034 you don't like about the series and
NOTE Confidence: 0.8736119

00:01:22.034 --> 00:01:24.370 how we can improve it going forward.
NOTE Confidence: 0.8736119

00:01:24.370 --> 00:01:26.540 This is the first time we're doing
NOTE Confidence: 0.8736119

00:01:26.540 --> 00:01:28.389 the hematology post ash highlights,
NOTE Confidence: 0.8736119

00:01:28.390 --> 00:01:30.830 and I hope to keep this going for
NOTE Confidence: 0.8736119

00:01:30.830 --> 00:01:33.475 the next few years with a combination
NOTE Confidence: 0.8736119

00:01:33.475 --> 00:01:35.435 of virtual and in person.
NOTE Confidence: 0.8736119

00:01:35.440 --> 00:01:37.765 Components, so for today's session
NOTE Confidence: 0.8736119

00:01:37.765 --> 00:01:41.055 it's a pleasure to have three of
NOTE Confidence: 0.8736119

00:01:41.055 --> 00:01:43.701 our faculty presenting and we will
NOTE Confidence: 0.8736119

00:01:43.701 --> 00:01:46.429 be starting with Doctor Schelling,
NOTE Confidence: 0.8736119

00:01:46.430 --> 00:01:48.805 Kothari or Assistant Professor of
NOTE Confidence: 0.8736119

00:01:48.805 --> 00:01:51.868 Medicine who will go over aggressive
NOTE Confidence: 0.8736119

00:01:51.868 --> 00:01:54.888 lymphoid malignancy's B cell type.

NOTE Confidence: 0.8736119

00:01:54.890 --> 00:01:56.662 Doctor Francis Commentary will

NOTE Confidence: 0.8736119

00:01:56.662 --> 00:01:59.941 cover for us the indolent B cell

NOTE Confidence: 0.8736119

00:01:59.941 --> 00:02:02.616 malignancies and Doctor Turchin City.

NOTE Confidence: 0.8736119

00:02:02.620 --> 00:02:05.320 Also Assistant Professor of

NOTE Confidence: 0.8736119

00:02:05.320 --> 00:02:08.020 Medicine will be covering.

NOTE Confidence: 0.8736119

00:02:08.020 --> 00:02:10.328 The T cell malignancies,

NOTE Confidence: 0.8736119

00:02:10.328 --> 00:02:12.636 both indolent and aggressive.

NOTE Confidence: 0.8736119

00:02:12.640 --> 00:02:15.664 At the end we will have a Q&A.

NOTE Confidence: 0.8736119

00:02:15.670 --> 00:02:17.798 The talks will be around 40 to 45

NOTE Confidence: 0.8736119

00:02:17.798 --> 00:02:19.861 minutes in total and the last 15

NOTE Confidence: 0.8736119

00:02:19.861 --> 00:02:21.590 minutes will have a question and

NOTE Confidence: 0.8736119

00:02:21.590 --> 00:02:23.084 answer session and this will be

NOTE Confidence: 0.8736119

00:02:23.084 --> 00:02:24.453 moderated by our Assistant Professor

NOTE Confidence: 0.8736119

00:02:24.453 --> 00:02:26.098 of Medicine Doctor Scott Huntington,

NOTE Confidence: 0.8736119

00:02:26.100 --> 00:02:28.473 who will be joining at the panel

NOTE Confidence: 0.8736119

00:02:28.473 --> 00:02:30.398 at the panel at the end.
NOTE Confidence: 0.8736119

00:02:30.400 --> 00:02:31.584 So without further ado,
NOTE Confidence: 0.8736119

00:02:31.584 --> 00:02:33.360 I'd like to introduce Doctor Schelling
NOTE Confidence: 0.8736119

00:02:33.417 --> 00:02:35.340 Kothari, who will start us off.
NOTE Confidence: 0.8736119

00:02:35.340 --> 00:02:35.960 Thank you.
NOTE Confidence: 0.6429361

00:02:37.940 --> 00:02:38.740 Thank you Amar.
NOTE Confidence: 0.7802936

00:02:44.400 --> 00:02:47.396 So today I'm going to talk about
NOTE Confidence: 0.7802936

00:02:47.396 --> 00:02:49.725 updates from Astronium 20 focusing
NOTE Confidence: 0.7802936

00:02:49.725 --> 00:02:52.120 on aggressive B cell informers.
NOTE Confidence: 0.7802936

00:02:52.120 --> 00:02:53.876 I'll cover for studies.
NOTE Confidence: 0.7802936

00:02:53.876 --> 00:02:56.510 One very heavily participated and we
NOTE Confidence: 0.7802936

00:02:56.587 --> 00:02:59.451 were one of the top accruing sites of
NOTE Confidence: 0.7802936

00:02:59.451 --> 00:03:02.299 oral triple combination of BTK number M,
NOTE Confidence: 0.7802936

00:03:02.300 --> 00:03:03.872 Tor inhibitor animite,
NOTE Confidence: 0.7802936

00:03:03.872 --> 00:03:05.968 and relapse refractory Richter's
NOTE Confidence: 0.7802936

00:03:05.968 --> 00:03:09.201 transformation and Dean over DL BCL and then

NOTE Confidence: 0.7802936

00:03:09.201 --> 00:03:11.658 I'll talk about more sooner to Zoom app,

NOTE Confidence: 0.7802936

00:03:11.660 --> 00:03:14.299 which is a T cell engaging bispecific

NOTE Confidence: 0.7802936

00:03:14.299 --> 00:03:16.130 antibody in aggressive lymphomas.

NOTE Confidence: 0.7802936

00:03:16.130 --> 00:03:19.058 I will not cover the other 3T cell

NOTE Confidence: 0.7802936

00:03:19.058 --> 00:03:20.610 engaging bispecific antibodies,

NOTE Confidence: 0.7802936

00:03:20.610 --> 00:03:23.106 but they were also presented at.

NOTE Confidence: 0.7802936

00:03:23.110 --> 00:03:25.230 Ash.

NOTE Confidence: 0.7802936

00:03:25.230 --> 00:03:27.449 3rd would be the Lima MRD project

NOTE Confidence: 0.7802936

00:03:27.449 --> 00:03:29.070 in mantle cell lymphoma.

NOTE Confidence: 0.7802936

00:03:29.070 --> 00:03:31.206 An Lastly roll off CNS prophylaxis

NOTE Confidence: 0.7802936

00:03:31.206 --> 00:03:32.910 in high risk DLP CL.

NOTE Confidence: 0.83004814

00:03:35.260 --> 00:03:37.825 So this is the first study is the once

NOTE Confidence: 0.83004814

00:03:37.825 --> 00:03:39.734 daily ordered triple combination of

NOTE Confidence: 0.83004814

00:03:39.734 --> 00:03:42.924 the three agents that I talked about in

NOTE Confidence: 0.83004814

00:03:42.924 --> 00:03:44.899 Richter's transformation and in over

NOTE Confidence: 0.83004814

00:03:44.899 --> 00:03:47.522 diffuse large B cell lymphoma. This was
NOTE Confidence: 0.83004814

00:03:47.522 --> 00:03:50.060 presented at ASH 2020 by Doctor Mato.
NOTE Confidence: 0.79723066

00:03:52.980 --> 00:03:56.118 Other preclinical studies.
NOTE Confidence: 0.79723066

00:03:56.120 --> 00:03:58.892 This was a national combination based
NOTE Confidence: 0.79723066

00:03:58.892 --> 00:04:00.740 on synthetic synthetic lethality.
NOTE Confidence: 0.79723066

00:04:00.740 --> 00:04:03.967 As you can see on the left,
NOTE Confidence: 0.79723066

00:04:03.970 --> 00:04:07.407 the tumor volume of in mice drastic
NOTE Confidence: 0.79723066

00:04:07.407 --> 00:04:09.951 drastically reduced in the triple
NOTE Confidence: 0.79723066

00:04:09.951 --> 00:04:12.406 combination arm in comparison to
NOTE Confidence: 0.79723066

00:04:12.406 --> 00:04:15.238 the vehicle or a single agent.
NOTE Confidence: 0.79723066

00:04:15.240 --> 00:04:18.264 On the right you just see the B
NOTE Confidence: 0.79723066

00:04:18.264 --> 00:04:20.727 cell receptor pathway and other
NOTE Confidence: 0.79723066

00:04:20.727 --> 00:04:22.887 pathways that further help.
NOTE Confidence: 0.79723066

00:04:22.890 --> 00:04:25.564 In Onco Genesis an how the triple
NOTE Confidence: 0.79723066

00:04:25.564 --> 00:04:27.812 combination therapy could help prevent
NOTE Confidence: 0.79723066

00:04:27.812 --> 00:04:29.884 tumor resistance by targetting

NOTE Confidence: 0.79723066

00:04:29.884 --> 00:04:31.438 different pathways together,

NOTE Confidence: 0.79723066

00:04:31.440 --> 00:04:33.240 namely employment pathway AKT,

NOTE Confidence: 0.79723066

00:04:33.240 --> 00:04:35.040 mtor pathway, BTK pathway,

NOTE Confidence: 0.79723066

00:04:35.040 --> 00:04:37.290 and I have four inhibition.

NOTE Confidence: 0.7799954

00:04:40.600 --> 00:04:43.588 The key eligibility criteria for this

NOTE Confidence: 0.7799954

00:04:43.588 --> 00:04:47.676 3 + 3 design is age more than 18.

NOTE Confidence: 0.7799954

00:04:47.680 --> 00:04:50.506 Life expectancy more than 12 weeks,

NOTE Confidence: 0.7799954

00:04:50.510 --> 00:04:52.870 with other standard inclusion criteria.

NOTE Confidence: 0.7799954

00:04:52.870 --> 00:04:56.486 The stage one, which is what we are

NOTE Confidence: 0.7799954

00:04:56.486 --> 00:04:59.480 presenting today is the BTK monotherapy,

NOTE Confidence: 0.7799954

00:04:59.480 --> 00:05:02.444 like not in combination in one

NOTE Confidence: 0.7799954

00:05:02.444 --> 00:05:05.388 pill but three separate pills of

NOTE Confidence: 0.7799954

00:05:05.388 --> 00:05:08.447 DRM 12 which is the BTK inhibitor.

NOTE Confidence: 0.7799954

00:05:08.450 --> 00:05:12.174 Novel became a bitter in combination with.

NOTE Confidence: 0.7799954

00:05:12.180 --> 00:05:15.480 Letter from Little Mind and

NOTE Confidence: 0.7799954

00:05:15.480 --> 00:05:18.120 everolimus and then eventually.
NOTE Confidence: 0.7799954

00:05:18.120 --> 00:05:19.975 We are will start accruing
NOTE Confidence: 0.7799954

00:05:19.975 --> 00:05:22.370 the Stage 2 instead of three,
NOTE Confidence: 0.7799954

00:05:22.370 --> 00:05:24.686 which is a single pill with
NOTE Confidence: 0.7799954

00:05:24.686 --> 00:05:26.230 three two different drugs,
NOTE Confidence: 0.7799954

00:05:26.230 --> 00:05:28.015 and then eventually all three
NOTE Confidence: 0.7799954

00:05:28.015 --> 00:05:30.296 drugs in one pill for patient
NOTE Confidence: 0.7799954

00:05:30.296 --> 00:05:32.396 convenience and ease of use.
NOTE Confidence: 0.7856527

00:05:34.690 --> 00:05:37.168 This is these other patient characteristics.
NOTE Confidence: 0.7856527

00:05:37.170 --> 00:05:39.654 Here you can see that in
NOTE Confidence: 0.7856527

00:05:39.654 --> 00:05:40.896 Richter's transformation panel,
NOTE Confidence: 0.7856527

00:05:40.900 --> 00:05:44.108 most patients had gotten our chop while in
NOTE Confidence: 0.7856527

00:05:44.108 --> 00:05:47.518 DLB seal all patients had gotten our job.
NOTE Confidence: 0.7856527

00:05:47.520 --> 00:05:50.010 So these patients were heavily treated.
NOTE Confidence: 0.7856527

00:05:50.010 --> 00:05:52.494 Median prior therapies were three in
NOTE Confidence: 0.7856527

00:05:52.494 --> 00:05:54.150 Victor's transformation into Indy.

NOTE Confidence: 0.7856527

00:05:54.150 --> 00:05:57.454 LBC, Elko hurt, so these were in general.

NOTE Confidence: 0.7856527

00:05:57.460 --> 00:06:01.006 The point is that they were

NOTE Confidence: 0.7856527

00:06:01.006 --> 00:06:02.779 heavily pretreated patients.

NOTE Confidence: 0.7856527

00:06:02.780 --> 00:06:05.010 At this is the data,

NOTE Confidence: 0.7856527

00:06:05.010 --> 00:06:07.230 so overall response rate in

NOTE Confidence: 0.7856527

00:06:07.230 --> 00:06:09.006 Richter's transformation is 46%,

NOTE Confidence: 0.7856527

00:06:09.010 --> 00:06:11.235 which is quite phenomenal in

NOTE Confidence: 0.7856527

00:06:11.235 --> 00:06:13.460 in such an aggressive disease,

NOTE Confidence: 0.7856527

00:06:13.460 --> 00:06:17.814 Indian over DLB sell, it was 45%.

NOTE Confidence: 0.7856527

00:06:17.820 --> 00:06:19.970 These are the CRN PR's.

NOTE Confidence: 0.8058844

00:06:22.840 --> 00:06:25.270 This is the waterfall plot,

NOTE Confidence: 0.8058844

00:06:25.270 --> 00:06:28.010 essentially looking at the

NOTE Confidence: 0.8058844

00:06:28.010 --> 00:06:30.750 percentage of tumor reduction.

NOTE Confidence: 0.8058844

00:06:30.750 --> 00:06:33.228 Yellow being the LBC, Ellen blue

NOTE Confidence: 0.8058844

00:06:33.228 --> 00:06:34.467 being Richter's transformation.

NOTE Confidence: 0.8058844

00:06:34.470 --> 00:06:37.438 You see that there is a significant
NOTE Confidence: 0.8058844

00:06:37.438 --> 00:06:39.840 tumor reduction in both the cohorts.
NOTE Confidence: 0.83258027

00:06:42.120 --> 00:06:45.530 Cytopenias were present for sure.
NOTE Confidence: 0.83258027

00:06:45.530 --> 00:06:48.930 Given the triple combination neutropenia,
NOTE Confidence: 0.83258027

00:06:48.930 --> 00:06:51.658 33% grade, 32% grade,
NOTE Confidence: 0.83258027

00:06:51.658 --> 00:06:54.380 42% Grade 3 thrombocytopenia,
NOTE Confidence: 0.83258027

00:06:54.380 --> 00:06:59.340 and 8% Grade 4 thrombocytopenia.
NOTE Confidence: 0.83258027

00:06:59.340 --> 00:07:01.740 The non heme toxicities were low.
NOTE Confidence: 0.83258027

00:07:01.740 --> 00:07:05.016 You know 4% odds are only in one patient
NOTE Confidence: 0.83258027

00:07:05.016 --> 00:07:08.538 and there were no grade for side effects.
NOTE Confidence: 0.83318603

00:07:11.040 --> 00:07:13.539 So the conclusion of this study was
NOTE Confidence: 0.83318603

00:07:13.539 --> 00:07:15.849 that the primary endpoint was met,
NOTE Confidence: 0.83318603

00:07:15.850 --> 00:07:17.640 that the triple combination therapy
NOTE Confidence: 0.83318603

00:07:17.640 --> 00:07:19.920 has an acceptable study safety profile.
NOTE Confidence: 0.83318603

00:07:19.920 --> 00:07:22.140 The main safety findings were expected
NOTE Confidence: 0.83318603

00:07:22.140 --> 00:07:25.036 and manageable, and currently we are

NOTE Confidence: 0.83318603

00:07:25.036 --> 00:07:28.270 accruing for the phase two study.

NOTE Confidence: 0.83318603

00:07:28.270 --> 00:07:30.085 It is underway targeting patients

NOTE Confidence: 0.83318603

00:07:30.085 --> 00:07:32.430 with novel agents exposed to relapse,

NOTE Confidence: 0.83318603

00:07:32.430 --> 00:07:34.735 refractory CLL and other non

NOTE Confidence: 0.83318603

00:07:34.735 --> 00:07:37.660 Hodgkin lymphoma's. Um?

NOTE Confidence: 0.83318603

00:07:37.660 --> 00:07:40.452 The next study I will talk about is

NOTE Confidence: 0.83318603

00:07:40.452 --> 00:07:42.980 the single agent motion resume AB,

NOTE Confidence: 0.83318603

00:07:42.980 --> 00:07:45.584 which is a T cell engaging bispecific

NOTE Confidence: 0.83318603

00:07:45.584 --> 00:07:48.574 antibody and this was presented by Doctor

NOTE Confidence: 0.83318603

00:07:48.574 --> 00:07:50.829 Adam Orlowski from Brown University.

NOTE Confidence: 0.83318603

00:07:50.830 --> 00:07:53.290 And this was studied in the

NOTE Confidence: 0.83318603

00:07:53.290 --> 00:07:54.110 frontline setting,

NOTE Confidence: 0.83318603

00:07:54.110 --> 00:07:57.206 so treatment naive elderly unfit patients

NOTE Confidence: 0.83318603

00:07:57.206 --> 00:08:00.529 with diffuse large B cell lymphoma.

NOTE Confidence: 0.83318603

00:08:00.530 --> 00:08:02.651 Up to 30% of patients aged more

NOTE Confidence: 0.83318603

00:08:02.651 --> 00:08:05.106 than 25 years do not receive
NOTE Confidence: 0.83318603

00:08:05.106 --> 00:08:06.585 standard chemo immunotherapy,
NOTE Confidence: 0.83318603

00:08:06.590 --> 00:08:09.150 so there is a lot of unmet need
NOTE Confidence: 0.83318603

00:08:09.150 --> 00:08:11.565 and there is need to develop
NOTE Confidence: 0.83318603

00:08:11.565 --> 00:08:13.675 therapies which are less toxic
NOTE Confidence: 0.83318603

00:08:13.675 --> 00:08:16.449 more sooner to some apples in IgG,
NOTE Confidence: 0.83318603

00:08:16.450 --> 00:08:17.899 one CD20 CD.
NOTE Confidence: 0.83318603

00:08:17.899 --> 00:08:19.831 Three bispecific antibody that
NOTE Confidence: 0.83318603

00:08:19.831 --> 00:08:22.787 redirects T cells to engage and
NOTE Confidence: 0.83318603

00:08:22.787 --> 00:08:24.687 eliminate malignant B cells.
NOTE Confidence: 0.83318603

00:08:24.690 --> 00:08:27.222 So here Doctor ourselves keep presented
NOTE Confidence: 0.83318603

00:08:27.222 --> 00:08:29.752 early clinical data with single agent
NOTE Confidence: 0.83318603

00:08:29.752 --> 00:08:32.468 most Natuzzi my best first line therapy.
NOTE Confidence: 0.83318603

00:08:32.470 --> 00:08:34.110 The key inclusion criterias,
NOTE Confidence: 0.83318603

00:08:34.110 --> 00:08:34.955 treatment, naive,
NOTE Confidence: 0.83318603

00:08:34.955 --> 00:08:35.825 ideal BCL,

NOTE Confidence: 0.83318603

00:08:35.825 --> 00:08:38.870 patients or high grade B cell informers

NOTE Confidence: 0.83318603

00:08:38.951 --> 00:08:41.759 for patients who were 60 to 79 they

NOTE Confidence: 0.83318603

00:08:41.759 --> 00:08:44.677 they would have to have impairment in

NOTE Confidence: 0.83318603

00:08:44.677 --> 00:08:47.366 adls or inability to tolerate full.

NOTE Confidence: 0.83318603

00:08:47.366 --> 00:08:50.096 Those immunotherapy for whatever reason.

NOTE Confidence: 0.83318603

00:08:50.100 --> 00:08:52.185 Just like with all other

NOTE Confidence: 0.83318603

00:08:52.185 --> 00:08:53.436 bispecific antibody trials,

NOTE Confidence: 0.83318603

00:08:53.440 --> 00:08:56.562 typically it's done in a ramp up

NOTE Confidence: 0.83318603

00:08:56.562 --> 00:08:59.729 fashion to decrease the chances and

NOTE Confidence: 0.83318603

00:08:59.729 --> 00:09:02.624 severity of cytokine release syndrome.

NOTE Confidence: 0.83318603

00:09:02.630 --> 00:09:05.924 Study design allowed pre face therapy

NOTE Confidence: 0.83318603

00:09:05.924 --> 00:09:08.664 with Prednisone and vincristine and

NOTE Confidence: 0.83318603

00:09:08.664 --> 00:09:11.430 responses estimates were done at interim

NOTE Confidence: 0.83318603

00:09:11.430 --> 00:09:15.205 cycle four in Cycle 8 and every six months.

NOTE Confidence: 0.83318603

00:09:15.210 --> 00:09:16.918 There are two doors.

NOTE Confidence: 0.83318603

00:09:16.918 --> 00:09:18.626 Levels are studied 13.5
NOTE Confidence: 0.83318603

00:09:18.626 --> 00:09:20.986 and 30 at the at day 15.
NOTE Confidence: 0.83318603

00:09:20.990 --> 00:09:23.474 So you start with one milligram
NOTE Confidence: 0.83318603

00:09:23.474 --> 00:09:25.610 to milligram in 13.5 or 1,
NOTE Confidence: 0.83318603

00:09:25.610 --> 00:09:26.765 two and 30,
NOTE Confidence: 0.83318603

00:09:26.765 --> 00:09:29.840 and then there was continued every 21 weeks.
NOTE Confidence: 0.8112449

00:09:32.300 --> 00:09:34.000 Patient population is shown here.
NOTE Confidence: 0.8112449

00:09:34.000 --> 00:09:36.094 So 29 elderly unfit patients were
NOTE Confidence: 0.8112449

00:09:36.094 --> 00:09:38.200 enrolled in this study of eight
NOTE Confidence: 0.8112449

00:09:38.200 --> 00:09:40.120 patients less than 80 years old.
NOTE Confidence: 0.8112449

00:09:40.120 --> 00:09:41.820 Five patients had impairment in
NOTE Confidence: 0.8112449

00:09:41.820 --> 00:09:44.200 renal function. As you can see here,
NOTE Confidence: 0.8112449

00:09:44.200 --> 00:09:47.270 performance status, you know 022.
NOTE Confidence: 0.8112449

00:09:47.270 --> 00:09:49.256 We do see clinically patients who
NOTE Confidence: 0.8112449

00:09:49.256 --> 00:09:50.580 have worse performance status,
NOTE Confidence: 0.8112449

00:09:50.580 --> 00:09:52.566 but given the clinical trial design,

NOTE Confidence: 0.8112449

00:09:52.570 --> 00:09:55.444 it isn't. It is quite understandable

NOTE Confidence: 0.8112449

00:09:55.444 --> 00:09:57.760 that they were enrolling 022.

NOTE Confidence: 0.8112449

00:09:57.760 --> 00:10:00.292 Quite a few. Almost 50% of Asia.

NOTE Confidence: 0.8112449

00:10:00.292 --> 00:10:02.998 With stage four disease and 50%

NOTE Confidence: 0.8112449

00:10:03.000 --> 00:10:04.644 with elevated elevated LDH,

NOTE Confidence: 0.8112449

00:10:04.644 --> 00:10:07.110 so overall a good real world

NOTE Confidence: 0.8112449

00:10:07.190 --> 00:10:09.690 characterization of patients here.

NOTE Confidence: 0.8114332

00:10:11.970 --> 00:10:13.834 Side effects were present,

NOTE Confidence: 0.8114332

00:10:13.834 --> 00:10:16.164 but relatively easy to manage,

NOTE Confidence: 0.8114332

00:10:16.170 --> 00:10:18.510 so rash, fatigue, abdominal pain,

NOTE Confidence: 0.8114332

00:10:18.510 --> 00:10:19.908 infusion related reaction,

NOTE Confidence: 0.8114332

00:10:19.908 --> 00:10:22.238 decreased appetite and dry mouth.

NOTE Confidence: 0.8114332

00:10:22.240 --> 00:10:25.048 Cytokine release syndrome was also present,

NOTE Confidence: 0.8114332

00:10:25.050 --> 00:10:27.840 but the grade three and four

NOTE Confidence: 0.8114332

00:10:27.840 --> 00:10:30.180 CRS events were very low.

NOTE Confidence: 0.8047372

00:10:32.430 --> 00:10:35.754 The best oral response rate was
NOTE Confidence: 0.8047372

00:10:35.754 --> 00:10:39.076 seen in in 6363.5% of patients
NOTE Confidence: 0.8047372

00:10:39.076 --> 00:10:42.394 and in the highest dose cohort,
NOTE Confidence: 0.8047372

00:10:42.400 --> 00:10:45.724 30 milligrams. 50% of the patients
NOTE Confidence: 0.8047372

00:10:45.724 --> 00:10:47.386 achieved complete response.
NOTE Confidence: 0.8276264

00:10:50.150 --> 00:10:52.185 This is still sure the
NOTE Confidence: 0.8276264

00:10:52.185 --> 00:10:53.406 durability of response.
NOTE Confidence: 0.8276264

00:10:53.410 --> 00:10:55.870 The ones in green are the
NOTE Confidence: 0.8276264

00:10:55.870 --> 00:10:57.510 patients with complete response
NOTE Confidence: 0.8276264

00:10:57.587 --> 00:10:59.963 and most of them continue to
NOTE Confidence: 0.8276264

00:10:59.963 --> 00:11:01.980 enjoy the durable response rate.
NOTE Confidence: 0.8276264

00:11:01.980 --> 00:11:03.640 Immediate duration of response
NOTE Confidence: 0.8276264

00:11:03.640 --> 00:11:06.589 was not reached and this is only
NOTE Confidence: 0.8276264

00:11:06.589 --> 00:11:08.917 a 5.4 months of median follow-up,
NOTE Confidence: 0.8276264

00:11:08.920 --> 00:11:12.224 so clearly very early data an we need
NOTE Confidence: 0.8276264

00:11:12.224 --> 00:11:15.449 to wait for the data too much or.

NOTE Confidence: 0.80800104

00:11:17.830 --> 00:11:20.302 So these are the authors conclusions

NOTE Confidence: 0.80800104

00:11:20.302 --> 00:11:22.853 early clinical data indicates that single

NOTE Confidence: 0.80800104

00:11:22.853 --> 00:11:24.948 agent is manageable and acceptable.

NOTE Confidence: 0.80800104

00:11:24.950 --> 00:11:26.578 Has acceptable safety profile.

NOTE Confidence: 0.80800104

00:11:26.578 --> 00:11:29.020 Encouraging efficacy was seen in this

NOTE Confidence: 0.80800104

00:11:29.081 --> 00:11:31.490 setting, an although they did some

NOTE Confidence: 0.80800104

00:11:31.490 --> 00:11:34.358 correlated studies and they did not find

NOTE Confidence: 0.80800104

00:11:34.358 --> 00:11:36.523 any clear Association with peripheral

NOTE Confidence: 0.80800104

00:11:36.523 --> 00:11:38.779 T cell activation and response.

NOTE Confidence: 0.80800104

00:11:38.780 --> 00:11:42.084 This paves way for either single agent or

NOTE Confidence: 0.80800104

00:11:42.084 --> 00:11:44.230 combination therapies with most senators.

NOTE Confidence: 0.80800104

00:11:44.230 --> 00:11:45.934 Mab in frontline setting,

NOTE Confidence: 0.80800104

00:11:45.934 --> 00:11:47.638 especially in elderly unfit.

NOTE Confidence: 0.80800104

00:11:47.640 --> 00:11:48.001 Patients.

NOTE Confidence: 0.80800104

00:11:48.001 --> 00:11:50.528 The third study I would like to

NOTE Confidence: 0.80800104

00:11:50.528 --> 00:11:53.021 talk about is the predictive power
NOTE Confidence: 0.80800104

00:11:53.021 --> 00:11:55.141 of early sequential MRD monitoring
NOTE Confidence: 0.80800104

00:11:55.141 --> 00:11:57.720 in mantle cell lymphoma following
NOTE Confidence: 0.80800104

00:11:57.720 --> 00:11:59.804 autologous stem cell transplantation
NOTE Confidence: 0.80800104

00:11:59.804 --> 00:12:03.949 with or without rituximab maintenance.
NOTE Confidence: 0.80800104

00:12:03.950 --> 00:12:06.542 This was presented by Doctor Callanan
NOTE Confidence: 0.80800104

00:12:06.542 --> 00:12:09.230 on behalf of the Lisa Group.
NOTE Confidence: 0.80800104

00:12:09.230 --> 00:12:12.158 The study was designed as such so the
NOTE Confidence: 0.80800104

00:12:12.158 --> 00:12:14.478 patients with classical mantle cell
NOTE Confidence: 0.80800104

00:12:14.478 --> 00:12:16.993 lymphoma had baseline MRD analysis
NOTE Confidence: 0.80800104

00:12:16.993 --> 00:12:20.269 done followed by 4 cycles of our dehab
NOTE Confidence: 0.80800104

00:12:20.269 --> 00:12:22.116 followed by pre autologous tense,
NOTE Confidence: 0.80800104

00:12:22.116 --> 00:12:22.492 transplant,
NOTE Confidence: 0.80800104

00:12:22.492 --> 00:12:25.124 MRD analysis and then you know high
NOTE Confidence: 0.80800104

00:12:25.124 --> 00:12:27.835 dose chemotherapy and then again post
NOTE Confidence: 0.80800104

00:12:27.835 --> 00:12:30.100 autologous transplant MRD analysis and

NOTE Confidence: 0.80800104
00:12:30.165 --> 00:12:32.613 then patients were either randomized to
NOTE Confidence: 0.80800104
00:12:32.613 --> 00:12:34.788 trucks or maintenance or observation.
NOTE Confidence: 0.80800104
00:12:34.788 --> 00:12:39.092 That type of MRD that was done was.
NOTE Confidence: 0.80800104
00:12:39.100 --> 00:12:39.935 Yeah,
NOTE Confidence: 0.80800104
00:12:39.935 --> 00:12:42.440 so IGHQ PCR.
NOTE Confidence: 0.80800104
00:12:42.440 --> 00:12:46.615 Looking at VDJ recombination region.
NOTE Confidence: 0.80800104
00:12:46.620 --> 00:12:48.948 Am the only talk about the first name
NOTE Confidence: 0.80800104
00:12:48.948 --> 00:12:51.336 given in interest of time is the
NOTE Confidence: 0.80800104
00:12:51.336 --> 00:12:53.548 prognostic impact of MRD status pre
NOTE Confidence: 0.80800104
00:12:53.548 --> 00:12:55.990 and post autologous stem cell transplant.
NOTE Confidence: 0.7600319
00:12:58.560 --> 00:13:00.947 This is the survival curve for pre
NOTE Confidence: 0.7600319
00:13:00.947 --> 00:13:02.720 autologous stem cell transplant,
NOTE Confidence: 0.7600319
00:13:02.720 --> 00:13:06.113 MRD status, so the one in red is MRD,
NOTE Confidence: 0.7600319
00:13:06.120 --> 00:13:08.731 negative green, blue is MRD positive so
NOTE Confidence: 0.7600319
00:13:08.731 --> 00:13:11.529 you can see that there is clear split
NOTE Confidence: 0.7600319

00:13:11.529 --> 00:13:14.489 in PFS and OS with improvement in PFS
NOTE Confidence: 0.7600319

00:13:14.489 --> 00:13:17.457 and OS in patients with MRD negativity.
NOTE Confidence: 0.80789965

00:13:19.620 --> 00:13:20.718 And hence essentially,
NOTE Confidence: 0.80789965

00:13:20.718 --> 00:13:23.280 this figure shows that there is a
NOTE Confidence: 0.80789965

00:13:23.351 --> 00:13:26.095 prognostic value in in doing MRD analysis.
NOTE Confidence: 0.80789965

00:13:26.100 --> 00:13:28.296 The next question that the authors
NOTE Confidence: 0.80789965

00:13:28.296 --> 00:13:31.646 looked at was to look at impact of
NOTE Confidence: 0.80789965

00:13:31.646 --> 00:13:33.906 maintenance therapy and MRD negative
NOTE Confidence: 0.80789965

00:13:33.906 --> 00:13:36.293 patients so the one the curve in
NOTE Confidence: 0.80789965

00:13:36.293 --> 00:13:38.286 red is patients who got Rituxan.
NOTE Confidence: 0.80789965

00:13:38.286 --> 00:13:40.932 Mab were but were not MRD negative
NOTE Confidence: 0.80789965

00:13:40.932 --> 00:13:44.035 and in blue is patients who are an
NOTE Confidence: 0.80789965

00:13:44.035 --> 00:13:46.733 observation and were MRD negative so you
NOTE Confidence: 0.80789965

00:13:46.733 --> 00:13:49.337 can see that even though these patients.
NOTE Confidence: 0.80789965

00:13:49.337 --> 00:13:52.353 MRD negative that is a clear split and
NOTE Confidence: 0.80789965

00:13:52.353 --> 00:13:55.225 that is you know statistically significant

NOTE Confidence: 0.80789965

00:13:55.225 --> 00:13:58.217 difference with PFS OS benefit in

NOTE Confidence: 0.80789965

00:13:58.217 --> 00:14:00.707 patients who got rituximab maintenance.

NOTE Confidence: 0.80789965

00:14:00.710 --> 00:14:02.640 The same thing holds true

NOTE Confidence: 0.80789965

00:14:02.640 --> 00:14:04.184 for post autologous stem,

NOTE Confidence: 0.80789965

00:14:04.190 --> 00:14:06.438 cell transplant, MRD also.

NOTE Confidence: 0.80789965

00:14:06.438 --> 00:14:09.430 Hence, the data is a bit humbling.

NOTE Confidence: 0.80789965

00:14:09.430 --> 00:14:11.726 Where we would you know would love

NOTE Confidence: 0.80789965

00:14:11.726 --> 00:14:14.680 to use MRD for therapeutic decisions,

NOTE Confidence: 0.80789965

00:14:14.680 --> 00:14:17.648 but it is pretty clear that maintenance

NOTE Confidence: 0.80789965

00:14:17.648 --> 00:14:19.891 rituximab still remains gold standard

NOTE Confidence: 0.80789965

00:14:19.891 --> 00:14:22.597 in classical mantle cell lymphoma and

NOTE Confidence: 0.80789965

00:14:22.597 --> 00:14:24.860 it's definitely a proof of concept

NOTE Confidence: 0.80789965

00:14:24.860 --> 00:14:27.198 that MRD is a good prognostic tool

NOTE Confidence: 0.80789965

00:14:27.198 --> 00:14:29.984 and should be used in addition to

NOTE Confidence: 0.80789965

00:14:29.984 --> 00:14:32.458 other tools such as pet imaging.

NOTE Confidence: 0.83317065

00:14:34.660 --> 00:14:37.145 Lastly, I will talk about CNS prophylaxis
NOTE Confidence: 0.83317065

00:14:37.145 --> 00:14:39.419 in aggressive non Hodgkin lymphoma's.
NOTE Confidence: 0.83317065

00:14:39.420 --> 00:14:42.521 There were two abstracts presented in the
NOTE Confidence: 0.83317065

00:14:42.521 --> 00:14:46.125 oral session at ASH 2020 and both kind of
NOTE Confidence: 0.83317065

00:14:46.125 --> 00:14:48.766 guide us in different directions in terms
NOTE Confidence: 0.83317065

00:14:48.766 --> 00:14:52.062 of what we do in clinics as of today,
NOTE Confidence: 0.83317065

00:14:52.062 --> 00:14:55.516 but there is a big caveat that both are
NOTE Confidence: 0.83317065

00:14:55.516 --> 00:14:58.150 retrospective studies and I would say
NOTE Confidence: 0.83317065

00:14:58.150 --> 00:15:01.641 that we need more prospective data before
NOTE Confidence: 0.83317065

00:15:01.641 --> 00:15:04.767 we change our or practice patterns.
NOTE Confidence: 0.83317065

00:15:04.770 --> 00:15:07.170 Traditionally, the CNS relapse risk
NOTE Confidence: 0.83317065

00:15:07.170 --> 00:15:10.300 is calculated as CNS IPI scoring,
NOTE Confidence: 0.83317065

00:15:10.300 --> 00:15:12.820 which includes age, ekach status,
NOTE Confidence: 0.83317065

00:15:12.820 --> 00:15:16.580 LDH, stage of the patient.
NOTE Confidence: 0.83317065

00:15:16.580 --> 00:15:19.574 The number of external sites and
NOTE Confidence: 0.83317065

00:15:19.574 --> 00:15:21.570 kidney and adrenal involvement.

NOTE Confidence: 0.83317065

00:15:21.570 --> 00:15:23.920 So patients who have intermediate

NOTE Confidence: 0.83317065

00:15:23.920 --> 00:15:27.928 or high CNS IPI score are thought to

NOTE Confidence: 0.83317065

00:15:27.928 --> 00:15:30.543 benefit from from CNS prophylaxis,

NOTE Confidence: 0.83317065

00:15:30.550 --> 00:15:33.050 mainly high dose Ivy methotrexate.

NOTE Confidence: 0.683736

00:15:35.370 --> 00:15:39.039 Rather than intrathecal methotrexate.

NOTE Confidence: 0.683736

00:15:39.040 --> 00:15:42.536 The first study that I'll talk about here.

NOTE Confidence: 0.683736

00:15:42.540 --> 00:15:45.886 Their objective was to determine if high

NOTE Confidence: 0.683736

00:15:45.886 --> 00:15:48.551 dose methotrexate reduced CNS relapse rates

NOTE Confidence: 0.683736

00:15:48.551 --> 00:15:51.454 and this was based in Alberta, Canada.

NOTE Confidence: 0.683736

00:15:51.454 --> 00:15:54.374 The design was retrospective include

NOTE Confidence: 0.683736

00:15:54.374 --> 00:15:58.995 patients were 18 to 70 years of age with

NOTE Confidence: 0.683736

00:15:58.995 --> 00:16:02.100 DL BCL treated between 2012 and 2019.

NOTE Confidence: 0.683736

00:16:02.100 --> 00:16:04.950 These patients CNS involvement at

NOTE Confidence: 0.683736

00:16:04.950 --> 00:16:10.128 diagnosis were excluded, as evident here.

NOTE Confidence: 0.683736

00:16:10.130 --> 00:16:12.468 What is interesting is that at this

NOTE Confidence: 0.683736

00:16:12.468 --> 00:16:14.324 site where they had identified
NOTE Confidence: 0.683736

00:16:14.324 --> 00:16:17.075 high risk patients only out of 326
NOTE Confidence: 0.683736

00:16:17.075 --> 00:16:18.780 identified high risk patients,
NOTE Confidence: 0.683736

00:16:18.780 --> 00:16:21.496 only 115 had gotten high dose methotrexate
NOTE Confidence: 0.683736

00:16:21.496 --> 00:16:24.156 for unknown reasons to under 911 patients
NOTE Confidence: 0.683736

00:16:24.156 --> 00:16:26.298 did not get high dose methotrexate,
NOTE Confidence: 0.683736

00:16:26.300 --> 00:16:28.788 so right off the bat you know since
NOTE Confidence: 0.683736

00:16:28.788 --> 00:16:31.558 we are analyzing only 115 patients,
NOTE Confidence: 0.683736

00:16:31.560 --> 00:16:33.985 it's difficult to make any
NOTE Confidence: 0.683736

00:16:33.985 --> 00:16:34.955 strong conclusions.
NOTE Confidence: 0.683736

00:16:34.960 --> 00:16:37.234 But here high dose methotrexate was
NOTE Confidence: 0.683736

00:16:37.234 --> 00:16:39.579 used was associated with younger age,
NOTE Confidence: 0.683736

00:16:39.580 --> 00:16:41.920 more the next one external site
NOTE Confidence: 0.683736

00:16:41.920 --> 00:16:43.480 could bring additional involvement
NOTE Confidence: 0.683736

00:16:43.548 --> 00:16:44.968 and double hit lymphoma.
NOTE Confidence: 0.83204776

00:16:47.040 --> 00:16:49.615 Multivariate analysis is shown here

NOTE Confidence: 0.83204776

00:16:49.615 --> 00:16:55.268 where you can see that the. There was no.

NOTE Confidence: 0.83204776

00:16:55.270 --> 00:16:57.450 Reflected high dose methotrexate did

NOTE Confidence: 0.83204776

00:16:57.450 --> 00:17:00.628 not show any improvement in CNS relapse

NOTE Confidence: 0.83204776

00:17:00.628 --> 00:17:03.869 and the same holds true for intensive

NOTE Confidence: 0.83204776

00:17:03.869 --> 00:17:05.850 immunochemotherapy such as our dose

NOTE Confidence: 0.83204776

00:17:05.850 --> 00:17:08.016 adjusted epoch or are high perceive.

NOTE Confidence: 0.83204776

00:17:08.020 --> 00:17:10.150 Add in comparison to R.

NOTE Confidence: 0.83204776

00:17:10.150 --> 00:17:11.425 Chop consolidative autologous

NOTE Confidence: 0.83204776

00:17:11.425 --> 00:17:13.125 stem cell transplantation was

NOTE Confidence: 0.83204776

00:17:13.125 --> 00:17:14.820 definitely showed more impact,

NOTE Confidence: 0.83204776

00:17:14.820 --> 00:17:18.720 although it did still cross the.

NOTE Confidence: 0.83204776

00:17:18.720 --> 00:17:21.848 Hazard ratio of 1.

NOTE Confidence: 0.83204776

00:17:21.850 --> 00:17:24.042 Here I'm showing multivariate

NOTE Confidence: 0.83204776

00:17:24.042 --> 00:17:26.782 analysis for PFS and OS.

NOTE Confidence: 0.83204776

00:17:26.790 --> 00:17:28.962 You can see that prophylactic high

NOTE Confidence: 0.83204776

00:17:28.962 --> 00:17:30.410 dose methotrexate and intensive
NOTE Confidence: 0.83204776

00:17:30.470 --> 00:17:32.975 immunochemotherapy did not show any
NOTE Confidence: 0.83204776

00:17:32.975 --> 00:17:34.478 statistically significant difference,
NOTE Confidence: 0.83204776

00:17:34.480 --> 00:17:36.188 although there was difference
NOTE Confidence: 0.83204776

00:17:36.188 --> 00:17:38.750 in PFS and OS in consolidative,
NOTE Confidence: 0.83204776

00:17:38.750 --> 00:17:41.890 autologous stem cell transplanted patients.
NOTE Confidence: 0.83204776

00:17:41.890 --> 00:17:44.120 Authors conclusions were there CNS
NOTE Confidence: 0.83204776

00:17:44.120 --> 00:17:47.052 relapse affect 6% of DCL patients and
NOTE Confidence: 0.83204776

00:17:47.052 --> 00:17:49.928 risk of CNS relapse or similar with
NOTE Confidence: 0.83204776

00:17:49.928 --> 00:17:52.364 or without high dose methotrexate and
NOTE Confidence: 0.83204776

00:17:52.364 --> 00:17:56.248 and as a proof of concept similar to
NOTE Confidence: 0.83204776

00:17:56.248 --> 00:17:58.833 rates reported in prior publications.
NOTE Confidence: 0.83204776

00:17:58.840 --> 00:18:00.835 Consolidative autologous stem
NOTE Confidence: 0.83204776

00:18:00.835 --> 00:18:03.495 cell transplantation or intensive
NOTE Confidence: 0.83204776

00:18:03.495 --> 00:18:06.357 immunochemotherapy trended to reduce CNS
NOTE Confidence: 0.83204776

00:18:06.357 --> 00:18:09.108 relapse of finding that is worthy of

NOTE Confidence: 0.83204776

00:18:09.108 --> 00:18:11.800 further study in a prospective setting.

NOTE Confidence: 0.83204776

00:18:11.800 --> 00:18:15.608 The other study that I will quickly go

NOTE Confidence: 0.83204776

00:18:15.608 --> 00:18:18.936 over before I hand over to Doctor said

NOTE Confidence: 0.83204776

00:18:18.936 --> 00:18:23.319 he is the CNS relapse by prophylaxis route.

NOTE Confidence: 0.83204776

00:18:23.320 --> 00:18:27.008 So the this study was a US multi

NOTE Confidence: 0.83204776

00:18:27.008 --> 00:18:29.400 center retrospective study where they

NOTE Confidence: 0.83204776

00:18:29.400 --> 00:18:32.627 found that from all the centers with

NOTE Confidence: 0.83204776

00:18:32.714 --> 00:18:35.768 patients 100 and 1000 patients total

NOTE Confidence: 0.83204776

00:18:35.768 --> 00:18:39.100 5.5% had overall CNS relapse rate of

NOTE Confidence: 0.83204776

00:18:39.100 --> 00:18:42.160 the patients who got into tickle.

NOTE Confidence: 0.83204776

00:18:42.160 --> 00:18:43.072 CNS prophylaxis,

NOTE Confidence: 0.83204776

00:18:43.072 --> 00:18:46.720 5.3% had CNS relapse and of the patients

NOTE Confidence: 0.83204776

00:18:46.800 --> 00:18:49.360 who got intravenous prophylaxis.

NOTE Confidence: 0.83204776

00:18:49.360 --> 00:18:52.438 Seven point, 1% had CNS relapse.

NOTE Confidence: 0.856802

00:18:54.700 --> 00:18:56.704 So there there are many other

NOTE Confidence: 0.856802

00:18:56.704 --> 00:18:58.040 findings from this study,
NOTE Confidence: 0.856802

00:18:58.040 --> 00:18:59.710 but in interest of time,
NOTE Confidence: 0.856802

00:18:59.710 --> 00:19:02.900 I'll briefly discuss their conclusions.
NOTE Confidence: 0.856802

00:19:02.900 --> 00:19:05.932 What I found interesting from this study was
NOTE Confidence: 0.856802

00:19:05.932 --> 00:19:09.196 that not only CNS IPI scoring is important,
NOTE Confidence: 0.856802

00:19:09.200 --> 00:19:11.408 but they also found a significant
NOTE Confidence: 0.856802

00:19:11.408 --> 00:19:13.793 CNS relapse rate in patients who
NOTE Confidence: 0.856802

00:19:13.793 --> 00:19:16.295 had involvement of testis or liver.
NOTE Confidence: 0.856802

00:19:16.300 --> 00:19:18.918 So that's something that we should keep
NOTE Confidence: 0.856802

00:19:18.918 --> 00:19:21.808 in mind in our clinics, but overall,
NOTE Confidence: 0.856802

00:19:21.808 --> 00:19:24.566 you know CNS relapse rates were similar,
NOTE Confidence: 0.856802

00:19:24.570 --> 00:19:25.356 following prophylaxis,
NOTE Confidence: 0.856802

00:19:25.356 --> 00:19:27.714 either intrathecal or high dose methotrexate.
NOTE Confidence: 0.856802

00:19:27.720 --> 00:19:30.485 They are going to do comparisons of
NOTE Confidence: 0.856802

00:19:30.485 --> 00:19:33.357 single versus dual route so intra ficke.
NOTE Confidence: 0.856802

00:19:33.360 --> 00:19:35.608 In high doses in the future and also

NOTE Confidence: 0.856802

00:19:35.608 --> 00:19:37.699 compare pro flexes and no pro flexes,

NOTE Confidence: 0.856802

00:19:37.700 --> 00:19:39.716 which would I think be of interest

NOTE Confidence: 0.856802

00:19:39.716 --> 00:19:41.490 to all of us?

NOTE Confidence: 0.856802

00:19:41.490 --> 00:19:43.580 But overall outcomes for following

NOTE Confidence: 0.856802

00:19:43.580 --> 00:19:46.227 CNS relapse remain poor without clear

NOTE Confidence: 0.856802

00:19:46.227 --> 00:19:48.657 benefit from existing treatment options.

NOTE Confidence: 0.90265936

00:19:50.710 --> 00:19:52.810 Thank you and please use the chat

NOTE Confidence: 0.90265936

00:19:52.810 --> 00:19:54.765 window for questions while we go

NOTE Confidence: 0.90265936

00:19:54.765 --> 00:19:56.097 along with more presentations.

NOTE Confidence: 0.92206365

00:20:42.590 --> 00:20:47.316 Hi everyone. So I'll be presenting

NOTE Confidence: 0.92206365

00:20:47.316 --> 00:20:50.236 the update on primarily focusing

NOTE Confidence: 0.92206365

00:20:50.236 --> 00:20:55.080 on the Salem farmers. And.

NOTE Confidence: 0.92206365

00:20:55.080 --> 00:20:57.957 So just one at a couple of

NOTE Confidence: 0.92206365

00:20:57.957 --> 00:21:00.040 abstracts for indolent lymphoma.

NOTE Confidence: 0.92206365

00:21:00.040 --> 00:21:02.300 I have no relevant disclosures.

NOTE Confidence: 0.897959

00:21:04.440 --> 00:21:07.247 So just starting with a brief overview.
NOTE Confidence: 0.7670744

00:21:09.300 --> 00:21:11.430 You know, dealing with the challenging
NOTE Confidence: 0.7670744

00:21:11.430 --> 00:21:13.580 field of T cell informers.
NOTE Confidence: 0.7670744

00:21:13.580 --> 00:21:16.380 You know there were a few studies
NOTE Confidence: 0.7670744

00:21:16.380 --> 00:21:18.639 that were presented that are off.
NOTE Confidence: 0.7670744

00:21:18.640 --> 00:21:21.760 Note that I'd like to highlight it in
NOTE Confidence: 0.7670744

00:21:21.760 --> 00:21:23.690 frontline peripheral T cell lymphoma.
NOTE Confidence: 0.7670744

00:21:23.690 --> 00:21:27.183 A couple of studies including the combination
NOTE Confidence: 0.7670744

00:21:27.183 --> 00:21:30.397 romidepsin job and as I said in chapter.
NOTE Confidence: 0.7670744

00:21:30.400 --> 00:21:33.004 Presented in relapsed refractory
NOTE Confidence: 0.7670744

00:21:33.004 --> 00:21:36.259 PTCL we had an update.
NOTE Confidence: 0.7670744

00:21:36.260 --> 00:21:38.960 On developer and relapsed refractory CDCR.
NOTE Confidence: 0.7670744

00:21:38.960 --> 00:21:41.210 There was a novel interleukin
NOTE Confidence: 0.7670744

00:21:41.210 --> 00:21:42.560 antagonist BNZ one,
NOTE Confidence: 0.7670744

00:21:42.560 --> 00:21:45.724 and then I will shift gears in
NOTE Confidence: 0.7670744

00:21:45.724 --> 00:21:49.617 touch on a couple of CLL studies.

NOTE Confidence: 0.7670744

00:21:49.620 --> 00:21:51.798 At the end.

NOTE Confidence: 0.7670744

00:21:51.800 --> 00:21:54.620 So talking about property selling

NOTE Confidence: 0.7670744

00:21:54.620 --> 00:21:57.440 former really the frontline treatment

NOTE Confidence: 0.7670744

00:21:57.528 --> 00:22:00.102 of this aggressive disease is a

NOTE Confidence: 0.7670744

00:22:00.102 --> 00:22:02.620 major area of clinical need and.

NOTE Confidence: 0.7864274

00:22:05.020 --> 00:22:07.882 You know, we most of us have been using

NOTE Confidence: 0.7864274

00:22:07.882 --> 00:22:11.472 CHOP or chop like regimens as the backbone

NOTE Confidence: 0.7864274

00:22:11.472 --> 00:22:14.220 chemotherapy backbone of frontline therapy.

NOTE Confidence: 0.7864274

00:22:14.220 --> 00:22:15.090 However, unfortunately,

NOTE Confidence: 0.7864274

00:22:15.090 --> 00:22:17.700 unlike diffuse large B cell lymphoma

NOTE Confidence: 0.7864274

00:22:17.700 --> 00:22:20.067 where our job has almost doubles,

NOTE Confidence: 0.7864274

00:22:20.070 --> 00:22:23.406 the CR rates that are seen with PTCL.

NOTE Confidence: 0.7864274

00:22:23.410 --> 00:22:26.602 So with PCL, which job we're looking

NOTE Confidence: 0.7864274

00:22:26.602 --> 00:22:30.516 at CR rates of just 35 to 40% in the

NOTE Confidence: 0.7864274

00:22:30.516 --> 00:22:32.606 setting of an aggressive lymphoma.

NOTE Confidence: 0.7864274

00:22:32.610 --> 00:22:34.896 This is really.
NOTE Confidence: 0.7864274

00:22:34.896 --> 00:22:37.944 A very challenging situation.
NOTE Confidence: 0.7864274

00:22:37.950 --> 00:22:40.966 Chip has been studied and shown to be
NOTE Confidence: 0.7864274

00:22:40.966 --> 00:22:44.105 of some limited success in certain in
NOTE Confidence: 0.7864274

00:22:44.105 --> 00:22:48.088 subtypes of patients in a subset of patients,
NOTE Confidence: 0.7864274

00:22:48.090 --> 00:22:51.618 specially those younger than 60 years of age.
NOTE Confidence: 0.7864274

00:22:51.620 --> 00:22:55.838 Much higher toxicity was seen in.
NOTE Confidence: 0.7864274

00:22:55.840 --> 00:23:01.034 Higher age group and those adjusted are.
NOTE Confidence: 0.7864274

00:23:01.040 --> 00:23:04.250 Suggested the bug is really considered
NOTE Confidence: 0.7864274

00:23:04.250 --> 00:23:08.182 for more aggressive subtypes like ATL and
NOTE Confidence: 0.7864274

00:23:08.182 --> 00:23:11.027 clinically aggressive presentations of PTCL.
NOTE Confidence: 0.7864274

00:23:11.030 --> 00:23:14.150 It's only recently that.
NOTE Confidence: 0.7864274

00:23:14.150 --> 00:23:16.382 No one study has changed the
NOTE Confidence: 0.7864274

00:23:16.382 --> 00:23:18.180 standard of care in CD.
NOTE Confidence: 0.7864274

00:23:18.180 --> 00:23:20.460 30 positive.
NOTE Confidence: 0.7864274

00:23:20.460 --> 00:23:22.490 TCL primarily in LCL Septics,

NOTE Confidence: 0.7864274

00:23:22.490 --> 00:23:25.298 where which where there was the most robust

NOTE Confidence: 0.7864274

00:23:25.298 --> 00:23:28.170 data for the combination of brentuximab,

NOTE Confidence: 0.7864274

00:23:28.170 --> 00:23:30.606 CHP from the Echelon two trial.

NOTE Confidence: 0.7864274

00:23:30.610 --> 00:23:33.730 But outside of this you know other studies

NOTE Confidence: 0.7864274

00:23:33.730 --> 00:23:36.789 that have tried to build on the chop

NOTE Confidence: 0.7864274

00:23:36.789 --> 00:23:39.539 backbone have not been very successful.

NOTE Confidence: 0.7840891

00:23:42.510 --> 00:23:45.989 So with this I'm going to present

NOTE Confidence: 0.7840891

00:23:45.989 --> 00:23:48.400 two frontline trials for PTCL,

NOTE Confidence: 0.7840891

00:23:48.400 --> 00:23:49.873 frontline treatment and

NOTE Confidence: 0.7840891

00:23:49.873 --> 00:23:52.328 so starting with Rd shop.

NOTE Confidence: 0.7840891

00:23:52.330 --> 00:23:56.080 So this was a phase three.

NOTE Confidence: 0.7840891

00:23:56.080 --> 00:23:59.280 A study conducted by the Lisa Group and

NOTE Confidence: 0.7840891

00:23:59.280 --> 00:24:02.550 again a frontline treatment of PTCL.

NOTE Confidence: 0.7840891

00:24:02.550 --> 00:24:06.240 It was presented by Doctor Vashi.

NOTE Confidence: 0.7840891

00:24:06.240 --> 00:24:08.802 So this study was based on the

NOTE Confidence: 0.7840891

00:24:08.802 --> 00:24:11.129 Phase 1B prior Phase 1B data.
NOTE Confidence: 0.83324665

00:24:13.490 --> 00:24:17.510 That showed. Basically a phase two
NOTE Confidence: 0.83324665

00:24:17.510 --> 00:24:20.567 dose of 12 milligram per meter squared
NOTE Confidence: 0.83324665

00:24:20.567 --> 00:24:23.745 was the one that was associated with,
NOTE Confidence: 0.83324665

00:24:23.750 --> 00:24:26.921 you know, but the best safety data
NOTE Confidence: 0.83324665

00:24:26.921 --> 00:24:30.974 given on day one and data for 21 day
NOTE Confidence: 0.83324665

00:24:30.974 --> 00:24:33.869 cycle with CHOP given on day one.
NOTE Confidence: 0.83324665

00:24:33.870 --> 00:24:36.070 This particular this is this
NOTE Confidence: 0.83324665

00:24:36.070 --> 00:24:37.830 prior study did have.
NOTE Confidence: 0.83324665

00:24:37.830 --> 00:24:41.169 Basically they give 8 cycles and a
NOTE Confidence: 0.83324665

00:24:41.169 --> 00:24:45.139 total of about 37 patients were studied.
NOTE Confidence: 0.83324665

00:24:45.140 --> 00:24:47.732 So in this present study presented
NOTE Confidence: 0.83324665

00:24:47.732 --> 00:24:49.028 by Doctor Bashi,
NOTE Confidence: 0.83324665

00:24:49.030 --> 00:24:51.325 this was a randomized controlled
NOTE Confidence: 0.83324665

00:24:51.325 --> 00:24:53.620 trial phase three data where
NOTE Confidence: 0.83324665

00:24:53.702 --> 00:24:55.507 the army was chop alone,

NOTE Confidence: 0.83324665

00:24:55.510 --> 00:24:58.096 and then I'm be had romidepsin,

NOTE Confidence: 0.83324665

00:24:58.100 --> 00:25:00.692 given in addition to chop again

NOTE Confidence: 0.83324665

00:25:00.692 --> 00:25:04.195 days 121 and eight at a dose of

NOTE Confidence: 0.83324665

00:25:04.195 --> 00:25:06.305 12 milligram per meter squared.

NOTE Confidence: 0.83324665

00:25:06.310 --> 00:25:09.325 The recommended phase two dose

NOTE Confidence: 0.83324665

00:25:09.325 --> 00:25:12.340 from the Phase 1B study.

NOTE Confidence: 0.83324665

00:25:12.340 --> 00:25:14.790 So in the study population,

NOTE Confidence: 0.83324665

00:25:14.790 --> 00:25:17.758 I do want to highlight that like

NOTE Confidence: 0.83324665

00:25:17.758 --> 00:25:20.670 many T cell lymphoma trials,

NOTE Confidence: 0.83324665

00:25:20.670 --> 00:25:24.294 it did include a very heterogeneous

NOTE Confidence: 0.83324665

00:25:24.294 --> 00:25:26.710 population of all aggressive

NOTE Confidence: 0.83324665

00:25:26.813 --> 00:25:30.305 histologies and then also looking at.

NOTE Confidence: 0.83324665

00:25:30.310 --> 00:25:32.746 One thing that is relevant really

NOTE Confidence: 0.83324665

00:25:32.746 --> 00:25:35.019 here is that patients undergoing

NOTE Confidence: 0.83324665

00:25:35.019 --> 00:25:37.319 autologous or allogeneic transplant

NOTE Confidence: 0.83324665

00:25:37.319 --> 00:25:39.619 planned as a consolidation
NOTE Confidence: 0.83324665

00:25:39.619 --> 00:25:42.119 were excluded from this study,
NOTE Confidence: 0.83324665

00:25:42.120 --> 00:25:47.027 which is really important to note because.
NOTE Confidence: 0.83324665

00:25:47.030 --> 00:25:48.682 A lot of people,
NOTE Confidence: 0.83324665

00:25:48.682 --> 00:25:50.747 even based on controversial data
NOTE Confidence: 0.83324665

00:25:50.747 --> 00:25:53.304 you consider autologous stem cell
NOTE Confidence: 0.83324665

00:25:53.304 --> 00:25:56.394 transplant for most patients who are
NOTE Confidence: 0.83324665

00:25:56.472 --> 00:25:59.082 eligible in first remission after
NOTE Confidence: 0.83324665

00:25:59.082 --> 00:26:01.692 after frontline treatment of PCL.
NOTE Confidence: 0.83324665

00:26:01.700 --> 00:26:04.556 The primary endpoint of this study
NOTE Confidence: 0.83324665

00:26:04.556 --> 00:26:07.055 was progression free survival and
NOTE Confidence: 0.83324665

00:26:07.055 --> 00:26:09.655 secondary endpoints included safety as
NOTE Confidence: 0.83324665

00:26:09.655 --> 00:26:12.560 well as additional efficacy endpoints.
NOTE Confidence: 0.83324665

00:26:12.560 --> 00:26:13.105 Again,
NOTE Confidence: 0.83324665

00:26:13.105 --> 00:26:15.830 baseline characteristics I want to
NOTE Confidence: 0.83324665

00:26:15.830 --> 00:26:18.918 highlight about half of the patients

NOTE Confidence: 0.83324665

00:26:18.918 --> 00:26:21.788 were of a ITL subtype and then,

NOTE Confidence: 0.83324665

00:26:21.790 --> 00:26:23.106 as expected,

NOTE Confidence: 0.83324665

00:26:23.106 --> 00:26:28.370 PCL and LCL where the other common subtypes.

NOTE Confidence: 0.83324665

00:26:28.370 --> 00:26:30.131 So here, unfortunately,

NOTE Confidence: 0.83324665

00:26:30.131 --> 00:26:32.479 like many other studies.

NOTE Confidence: 0.83324665

00:26:32.480 --> 00:26:34.958 But that have used chopped backbone.

NOTE Confidence: 0.83324665

00:26:34.960 --> 00:26:37.228 This was a this study did not

NOTE Confidence: 0.83324665

00:26:37.228 --> 00:26:39.379 meet its primary endpoint of

NOTE Confidence: 0.83324665

00:26:39.379 --> 00:26:41.587 improved progression free survival.

NOTE Confidence: 0.83324665

00:26:41.590 --> 00:26:44.269 The hazard ratio.

NOTE Confidence: 0.83324665

00:26:44.270 --> 00:26:49.262 For Rd shop versus R Chop Chop was

NOTE Confidence: 0.83324665

00:26:49.262 --> 00:26:53.635 appointed one with a P value of .096.

NOTE Confidence: 0.83324665

00:26:53.640 --> 00:26:54.694 And again,

NOTE Confidence: 0.83324665

00:26:54.694 --> 00:26:57.329 a subgroup analysis based on

NOTE Confidence: 0.83324665

00:26:57.329 --> 00:26:59.790 where this IPI factors.

NOTE Confidence: 0.83324665

00:26:59.790 --> 00:27:02.208 As well as histologies did not
NOTE Confidence: 0.83324665

00:27:02.208 --> 00:27:03.820 really show any significant
NOTE Confidence: 0.83324665

00:27:03.891 --> 00:27:06.146 subsets that were that achieve
NOTE Confidence: 0.83324665

00:27:06.146 --> 00:27:08.401 greater benefit from this regimen.
NOTE Confidence: 0.83324665

00:27:08.410 --> 00:27:11.427 But patients with AI TL did have.
NOTE Confidence: 0.83324665

00:27:11.430 --> 00:27:15.120 There was a trend too.
NOTE Confidence: 0.83324665

00:27:15.120 --> 00:27:17.796 Some benefit in this particular population,
NOTE Confidence: 0.83324665

00:27:17.800 --> 00:27:20.035 again looking at the overall
NOTE Confidence: 0.83324665

00:27:20.035 --> 00:27:22.270 and the complete response rates,
NOTE Confidence: 0.83324665

00:27:22.270 --> 00:27:24.500 the complete response rate was
NOTE Confidence: 0.83324665

00:27:24.500 --> 00:27:26.654 41% compared with 37%,
NOTE Confidence: 0.83324665

00:27:26.654 --> 00:27:28.926 which is consistent with
NOTE Confidence: 0.83324665

00:27:28.926 --> 00:27:31.880 historical data that we have from.
NOTE Confidence: 0.83324665

00:27:31.880 --> 00:27:36.910 Job. Again, without.
NOTE Confidence: 0.83324665

00:27:36.910 --> 00:27:39.230 Fighting any increase, additional efficacy.
NOTE Confidence: 0.83324665

00:27:39.230 --> 00:27:41.540 Rd job was more toxic.

NOTE Confidence: 0.83324665

00:27:41.540 --> 00:27:44.105 A substantial number of patients

NOTE Confidence: 0.83324665

00:27:44.105 --> 00:27:47.183 were not able to receive all

NOTE Confidence: 0.83324665

00:27:47.183 --> 00:27:49.721 doses of romidepsin as well as

NOTE Confidence: 0.83324665

00:27:49.721 --> 00:27:53.060 job and also significant number of

NOTE Confidence: 0.83324665

00:27:53.060 --> 00:27:55.040 patients are received.

NOTE Confidence: 0.83324665

00:27:55.040 --> 00:27:57.800 Had to undergo jobs reduction or

NOTE Confidence: 0.83324665

00:27:57.800 --> 00:28:00.340 interruption because of increased toxicity,

NOTE Confidence: 0.83324665

00:28:00.340 --> 00:28:03.840 which is primarily increased.

NOTE Confidence: 0.83324665

00:28:03.840 --> 00:28:07.386 Haematological toxicity so really,

NOTE Confidence: 0.83324665

00:28:07.386 --> 00:28:09.776 in summary for this study,

NOTE Confidence: 0.83324665

00:28:09.780 --> 00:28:12.515 Roach up increase toxicity without

NOTE Confidence: 0.83324665

00:28:12.515 --> 00:28:14.703 improving efficacy in frontline

NOTE Confidence: 0.83324665

00:28:14.703 --> 00:28:17.079 treatment of PTCL possible future

NOTE Confidence: 0.83324665

00:28:17.079 --> 00:28:19.274 directions really is based on

NOTE Confidence: 0.83324665

00:28:19.274 --> 00:28:21.726 whether CHOP is the right backbone.

NOTE Confidence: 0.83324665

00:28:21.730 --> 00:28:23.602 We do notes there.
NOTE Confidence: 0.83324665

00:28:23.602 --> 00:28:25.942 Drugs like romidepsin are more
NOTE Confidence: 0.83324665

00:28:25.942 --> 00:28:28.330 active in certain subtypes of
NOTE Confidence: 0.83324665

00:28:28.330 --> 00:28:31.084 PTCL like PTCL with T follicular
NOTE Confidence: 0.719972

00:28:31.175 --> 00:28:34.320 helper, cell subtype and AI TL
NOTE Confidence: 0.719972

00:28:34.320 --> 00:28:36.880 and so maybe's patient selection.
NOTE Confidence: 0.719972

00:28:36.880 --> 00:28:40.520 And based on Histology and then there
NOTE Confidence: 0.719972

00:28:40.520 --> 00:28:43.528 is another trial that is being.
NOTE Confidence: 0.719972

00:28:43.530 --> 00:28:46.008 And that is yet to start accruing.
NOTE Confidence: 0.719972

00:28:46.010 --> 00:28:48.236 But it's basically has been proposed
NOTE Confidence: 0.719972

00:28:48.236 --> 00:28:50.785 by NCI where they're looking at the
NOTE Confidence: 0.719972

00:28:50.785 --> 00:28:53.109 combination of Doxorubicin 5 as a as
NOTE Confidence: 0.719972

00:28:53.177 --> 00:28:55.592 a sighted in oral and then romidepsin
NOTE Confidence: 0.719972

00:28:55.592 --> 00:28:58.038 and develops it in T cell lymphoma.
NOTE Confidence: 0.8498516

00:29:00.270 --> 00:29:01.806 So those would be, you know,
NOTE Confidence: 0.8498516

00:29:01.810 --> 00:29:04.228 interesting things to look forward to.

NOTE Confidence: 0.8498516

00:29:04.230 --> 00:29:07.308 Our next study that was presented

NOTE Confidence: 0.8498516

00:29:07.308 --> 00:29:09.920 in Frontline PTCL was oral,

NOTE Confidence: 0.8498516

00:29:09.920 --> 00:29:13.016 is cited in CC-486 plus job.

NOTE Confidence: 0.8498516

00:29:13.020 --> 00:29:15.820 This was presented by

NOTE Confidence: 0.8498516

00:29:15.820 --> 00:29:18.620 Doctor Rowan from Kernel.

NOTE Confidence: 0.8498516

00:29:18.620 --> 00:29:20.865 So again, this particular study

NOTE Confidence: 0.8498516

00:29:20.865 --> 00:29:23.110 actually highlighted the point that

NOTE Confidence: 0.8498516

00:29:23.186 --> 00:29:25.629 an oral PCL with T follicular helper

NOTE Confidence: 0.8498516

00:29:25.629 --> 00:29:27.820 cell subtype is associated with.

NOTE Confidence: 0.69032043

00:29:30.380 --> 00:29:31.760 My hyperventilating mutations

NOTE Confidence: 0.69032043

00:29:31.760 --> 00:29:35.944 in the Ted in Ted 2D N MT3A and

NOTE Confidence: 0.69032043

00:29:35.944 --> 00:29:38.982 IDH 2 an in addition also roue

NOTE Confidence: 0.69032043

00:29:38.982 --> 00:29:41.806 mutations and this was the rational.

NOTE Confidence: 0.69032043

00:29:41.810 --> 00:29:44.342 These mutations are not only present

NOTE Confidence: 0.69032043

00:29:44.342 --> 00:29:47.567 in the two T follicular helper cell

NOTE Confidence: 0.69032043

00:29:47.567 --> 00:29:50.941 subtype AI TL but also some PTCL,
NOTE Confidence: 0.69032043

00:29:50.950 --> 00:29:55.248 PTCL nosc and so that was the
NOTE Confidence: 0.69032043

00:29:55.248 --> 00:29:58.730 rationale for using is cited in.
NOTE Confidence: 0.69032043

00:29:58.730 --> 00:30:01.244 As an epigenetic.
NOTE Confidence: 0.69032043

00:30:01.244 --> 00:30:03.758 Timer with chop.
NOTE Confidence: 0.69032043

00:30:03.760 --> 00:30:05.950 So this they proceeded straight to
NOTE Confidence: 0.69032043

00:30:05.950 --> 00:30:08.559 a phase two study because there was
NOTE Confidence: 0.69032043

00:30:08.559 --> 00:30:11.065 Phase one data for safety of this
NOTE Confidence: 0.69032043

00:30:11.140 --> 00:30:13.460 combination from B cell lymphoma.
NOTE Confidence: 0.69032043

00:30:13.460 --> 00:30:15.364 Uh, the they do.
NOTE Confidence: 0.69032043

00:30:15.364 --> 00:30:18.220 They do include all PTCL subsets.
NOTE Confidence: 0.69032043

00:30:18.220 --> 00:30:21.100 However they did prioritize enrollment
NOTE Confidence: 0.69032043

00:30:21.100 --> 00:30:24.432 of the T follicular helper cells
NOTE Confidence: 0.69032043

00:30:24.432 --> 00:30:27.699 upset and as you will see of the 20
NOTE Confidence: 0.69032043

00:30:27.791 --> 00:30:31.067 patients 17 where of TFH subset here?
NOTE Confidence: 0.69032043

00:30:31.070 --> 00:30:33.535 The primary endpoint was complete

NOTE Confidence: 0.69032043

00:30:33.535 --> 00:30:36.000 response rate and secondary endpoint

NOTE Confidence: 0.69032043

00:30:36.079 --> 00:30:38.689 was overall response rate and safety.

NOTE Confidence: 0.69032043

00:30:38.690 --> 00:30:41.690 They also looked at some genomic

NOTE Confidence: 0.69032043

00:30:41.690 --> 00:30:44.830 markers so this was an. Interesting.

NOTE Confidence: 0.801746250000001

00:30:47.220 --> 00:30:50.286 Study design and treatment regimen where

NOTE Confidence: 0.801746250000001

00:30:50.286 --> 00:30:53.726 initially CC 486 was given as a lead

NOTE Confidence: 0.801746250000001

00:30:53.726 --> 00:30:57.128 in from day minus 6 two day one for

NOTE Confidence: 0.801746250000001

00:30:57.128 --> 00:30:59.840 the first cycle and then subsequently

NOTE Confidence: 0.801746250000001

00:30:59.840 --> 00:31:03.848 from and subsequently four cycles.

NOTE Confidence: 0.801746250000001

00:31:03.850 --> 00:31:09.160 125 they received CC-486 on.

NOTE Confidence: 0.801746250000001

00:31:09.160 --> 00:31:11.728 Days 8 to 21 which basically

NOTE Confidence: 0.801746250000001

00:31:11.728 --> 00:31:14.509 so every so for cycle one.

NOTE Confidence: 0.801746250000001

00:31:14.510 --> 00:31:17.331 So this present this acted as priming

NOTE Confidence: 0.801746250000001

00:31:17.331 --> 00:31:20.760 phase for the next cycle of chemotherapy.

NOTE Confidence: 0.838634521428572

00:31:23.600 --> 00:31:27.744 So. After 21 patients that were enrolled,

NOTE Confidence: 0.838634521428572

00:31:27.750 --> 00:31:29.995 20 were evaluable for response
NOTE Confidence: 0.838634521428572

00:31:29.995 --> 00:31:32.980 and of these almost half of them.
NOTE Confidence: 0.838634521428572

00:31:32.980 --> 00:31:36.361 These patients actually did go on to
NOTE Confidence: 0.838634521428572

00:31:36.361 --> 00:31:38.805 receive autologous stem cell transplant
NOTE Confidence: 0.838634521428572

00:31:38.805 --> 00:31:41.997 or or one patient who received Alo.
NOTE Confidence: 0.838634521428572

00:31:42.000 --> 00:31:44.933 Here we see the overall CR overall
NOTE Confidence: 0.838634521428572

00:31:44.933 --> 00:31:47.997 response rate in CR rate in these
NOTE Confidence: 0.838634521428572

00:31:47.997 --> 00:31:50.142 patients in these 20 patients,
NOTE Confidence: 0.838634521428572

00:31:50.150 --> 00:31:52.592 and of all, all patients considering
NOTE Confidence: 0.838634521428572

00:31:52.592 --> 00:31:55.628 all patients as well as patients with
NOTE Confidence: 0.838634521428572

00:31:55.628 --> 00:31:58.292 PTCL default color helper cell subtype.
NOTE Confidence: 0.838634521428572

00:31:58.300 --> 00:32:01.348 It was seen that.
NOTE Confidence: 0.838634521428572

00:32:01.350 --> 00:32:05.598 88% CR rate was seen in TFs subtype
NOTE Confidence: 0.838634521428572

00:32:05.598 --> 00:32:08.132 compared with 75% all comers.
NOTE Confidence: 0.838634521428572

00:32:08.132 --> 00:32:10.712 Really, majority of the patients
NOTE Confidence: 0.838634521428572

00:32:10.712 --> 00:32:13.100 were of TFs subtype.

NOTE Confidence: 0.838634521428572
00:32:13.100 --> 00:32:15.739 Here are the results from the here.
NOTE Confidence: 0.838634521428572
00:32:15.740 --> 00:32:16.811 The survival curves,
NOTE Confidence: 0.838634521428572
00:32:16.811 --> 00:32:19.890 so the median follow up of 15 months.
NOTE Confidence: 0.8173223
00:32:22.490 --> 00:32:26.311 One year PFS was 66% for all patients
NOTE Confidence: 0.8173223
00:32:26.311 --> 00:32:29.650 and one year overall survival was 80%
NOTE Confidence: 0.8173223
00:32:29.650 --> 00:32:32.035 and the corresponding numbers for
NOTE Confidence: 0.8173223
00:32:32.035 --> 00:32:35.370 TFs subtype were almost 70% and 94%.
NOTE Confidence: 0.8525541
00:32:37.580 --> 00:32:41.360 This was a relatively well tolerated
NOTE Confidence: 0.8525541
00:32:41.360 --> 00:32:45.080 regimen with expected side effects of.
NOTE Confidence: 0.8525541
00:32:45.080 --> 00:32:47.400 Aside opinion, specially neutropenia,
NOTE Confidence: 0.8525541
00:32:47.400 --> 00:32:50.880 but other than the hematological toxicity,
NOTE Confidence: 0.8525541
00:32:50.880 --> 00:32:53.548 there were no additional
NOTE Confidence: 0.8525541
00:32:53.548 --> 00:32:56.216 significant unexpected side effects.
NOTE Confidence: 0.8525541
00:32:56.220 --> 00:32:57.772 This study also looked
NOTE Confidence: 0.8525541
00:32:57.772 --> 00:32:58.936 at mutational analysis,
NOTE Confidence: 0.8525541

00:32:58.940 --> 00:33:01.196 and it's worth mentioning that they
NOTE Confidence: 0.8525541

00:33:01.196 --> 00:33:03.194 found that tattoo was associated
NOTE Confidence: 0.8525541

00:33:03.194 --> 00:33:05.726 with a favorable prognosis in this
NOTE Confidence: 0.8525541

00:33:05.726 --> 00:33:07.859 cohort of patients and DMD MT3.
NOTE Confidence: 0.8525541

00:33:07.860 --> 00:33:09.412 Oh was associated with
NOTE Confidence: 0.8525541

00:33:09.412 --> 00:33:10.576 worse overall survival.
NOTE Confidence: 0.8612848

00:33:13.070 --> 00:33:15.086 So this was a surprisingly promising
NOTE Confidence: 0.8612848

00:33:15.086 --> 00:33:17.250 study and of this combination.
NOTE Confidence: 0.8612848

00:33:17.250 --> 00:33:19.545 Again, this is very early
NOTE Confidence: 0.8612848

00:33:19.545 --> 00:33:21.840 data of only 20 patients.
NOTE Confidence: 0.8612848

00:33:21.840 --> 00:33:24.666 So this is a, you know,
NOTE Confidence: 0.8612848

00:33:24.670 --> 00:33:27.974 a combination that is being tested further.
NOTE Confidence: 0.8612848

00:33:27.980 --> 00:33:30.782 One particular study that is worth
NOTE Confidence: 0.8612848

00:33:30.782 --> 00:33:33.170 highlighting is this alliance study,
NOTE Confidence: 0.8612848

00:33:33.170 --> 00:33:37.229 which is actually going to be rich is going
NOTE Confidence: 0.8612848

00:33:37.229 --> 00:33:41.416 to include patients with a C30 negative.

NOTE Confidence: 0.8612848

00:33:41.420 --> 00:33:44.087 PTCL non alc else Histology and it

NOTE Confidence: 0.8612848

00:33:44.087 --> 00:33:47.652 has it had three comparator arms one

NOTE Confidence: 0.8612848

00:33:47.652 --> 00:33:50.572 including CC 4861 including development

NOTE Confidence: 0.8612848

00:33:50.572 --> 00:33:54.493 and the third one is Chopper show up here

NOTE Confidence: 0.8612848

00:33:54.493 --> 00:33:57.154 with these combination they are using

NOTE Confidence: 0.8612848

00:33:57.154 --> 00:34:00.400 the backbone of Cho Absolute as well.

NOTE Confidence: 0.8612848

00:34:00.400 --> 00:34:04.636 It'll be worth looking at the.

NOTE Confidence: 0.8612848

00:34:04.640 --> 00:34:10.930 We can see. Of this these combinations.

NOTE Confidence: 0.8612848

00:34:10.930 --> 00:34:13.695 Next, I'd like to go onto a

NOTE Confidence: 0.8612848

00:34:13.695 --> 00:34:15.830 study with Dabella sub again,

NOTE Confidence: 0.8612848

00:34:15.830 --> 00:34:17.458 another promising new agent

NOTE Confidence: 0.8612848

00:34:17.458 --> 00:34:19.086 and T cell lymphoma.

NOTE Confidence: 0.8612848

00:34:19.090 --> 00:34:21.255 This was in relapsed refractory

NOTE Confidence: 0.8612848

00:34:21.255 --> 00:34:23.420 peripheral T cell lymphoma and

NOTE Confidence: 0.8612848

00:34:23.496 --> 00:34:25.758 this was updated data from the

NOTE Confidence: 0.8612848

00:34:25.758 --> 00:34:28.139 phase two Premier trial where they

NOTE Confidence: 0.8612848

00:34:28.139 --> 00:34:30.129 looking at those optimization and

NOTE Confidence: 0.8612848

00:34:30.129 --> 00:34:32.822 I'll go over that a little bit.

NOTE Confidence: 0.8612848

00:34:32.822 --> 00:34:34.687 This was presented by Doctor

NOTE Confidence: 0.8612848

00:34:34.687 --> 00:34:36.229 Pro from Northwest.

NOTE Confidence: 0.7310265

00:34:38.660 --> 00:34:40.922 So dualism is a dual appear

NOTE Confidence: 0.7310265

00:34:40.922 --> 00:34:42.430 three kindness Delta inhibitor.

NOTE Confidence: 0.7310265

00:34:42.430 --> 00:34:44.686 We know that is FDA approved

NOTE Confidence: 0.7310265

00:34:44.686 --> 00:34:45.814 in relapsed refractory,

NOTE Confidence: 0.7310265

00:34:45.820 --> 00:34:47.730 follicular lymphoma and CLL and

NOTE Confidence: 0.7310265

00:34:47.730 --> 00:34:50.082 the doors in these patients in

NOTE Confidence: 0.7310265

00:34:50.082 --> 00:34:51.957 these two diseases they approved

NOTE Confidence: 0.7310265

00:34:51.957 --> 00:34:54.241 doses 25 milligram vid when they

NOTE Confidence: 0.7310265

00:34:54.241 --> 00:34:56.377 tested this dosin T cell lymphoma.

NOTE Confidence: 0.7310265

00:34:56.380 --> 00:34:58.732 the Mac the MTD was 75 milligram

NOTE Confidence: 0.7310265

00:34:58.732 --> 00:35:01.324 PID vid and that was the dose

NOTE Confidence: 0.7310265

00:35:01.324 --> 00:35:03.574 tested in T cell lymphoma which

NOTE Confidence: 0.7310265

00:35:03.651 --> 00:35:05.726 showed an overall response rate

NOTE Confidence: 0.7310265

00:35:05.726 --> 00:35:07.688 of 50% in relapsed refractory,

NOTE Confidence: 0.7310265

00:35:07.688 --> 00:35:10.988 PTCL and 33% in cutaneous T cell.

NOTE Confidence: 0.7310265

00:35:10.988 --> 00:35:11.530 Former.

NOTE Confidence: 0.7310265

00:35:11.530 --> 00:35:14.202 So the reason that was the reason for

NOTE Confidence: 0.7310265

00:35:14.202 --> 00:35:16.155 designing this dose optimization study

NOTE Confidence: 0.7310265

00:35:16.155 --> 00:35:18.585 was to see whether these patients

NOTE Confidence: 0.7310265

00:35:18.585 --> 00:35:20.727 truly need 75 milligrams po BID.

NOTE Confidence: 0.7310265

00:35:20.730 --> 00:35:24.250 Or are we overtreating them?

NOTE Confidence: 0.7310265

00:35:24.250 --> 00:35:25.778 So the study design.

NOTE Confidence: 0.7310265

00:35:25.778 --> 00:35:28.045 Again, there was a dose optimization

NOTE Confidence: 0.7310265

00:35:28.045 --> 00:35:30.350 phase followed by those expansion phase.

NOTE Confidence: 0.7310265

00:35:30.350 --> 00:35:32.858 It did include.

NOTE Confidence: 0.7310265

00:35:32.860 --> 00:35:34.520 The various,

NOTE Confidence: 0.7310265

00:35:34.520 --> 00:35:39.500 not subtypes that we discussed and.
NOTE Confidence: 0.7310265

00:35:39.500 --> 00:35:42.349 So develop the cohort one included patient
NOTE Confidence: 0.7310265

00:35:42.349 --> 00:35:44.799 develops if patients received develops.
NOTE Confidence: 0.7310265

00:35:44.800 --> 00:35:48.336 If 25 milligram B ID and cohort two.
NOTE Confidence: 0.7310265

00:35:48.340 --> 00:35:50.108 They received 75 milligram
NOTE Confidence: 0.7310265

00:35:50.108 --> 00:35:52.318 vid as the starting dose.
NOTE Confidence: 0.7310265

00:35:52.320 --> 00:35:54.525 The primary endpoint was overall
NOTE Confidence: 0.7310265

00:35:54.525 --> 00:35:57.279 response rate with these two doses
NOTE Confidence: 0.7310265

00:35:57.279 --> 00:35:59.629 and then the secondary endpoints
NOTE Confidence: 0.7310265

00:35:59.629 --> 00:36:01.509 again looked at additional
NOTE Confidence: 0.7310265

00:36:01.588 --> 00:36:03.760 safety and efficacy endpoints.
NOTE Confidence: 0.7310265

00:36:03.760 --> 00:36:07.459 So here we are looking at cohort one and
NOTE Confidence: 0.7310265

00:36:07.459 --> 00:36:11.226 go to each had 13 evaluable patients.
NOTE Confidence: 0.7310265

00:36:11.230 --> 00:36:13.570 So the overall response rates.
NOTE Confidence: 0.7310265

00:36:13.570 --> 00:36:16.366 Sorry so the overall response rates.
NOTE Confidence: 0.7310265

00:36:16.370 --> 00:36:20.246 Seen here with the 25 milligram.

NOTE Confidence: 0.7310265

00:36:20.250 --> 00:36:23.862 I was basically 35 to 40% by the

NOTE Confidence: 0.7310265

00:36:23.862 --> 00:36:25.726 investigator and the committee

NOTE Confidence: 0.7310265

00:36:25.726 --> 00:36:28.472 and compared with 75 it was

NOTE Confidence: 0.7310265

00:36:28.472 --> 00:36:30.076 a higher response rate.

NOTE Confidence: 0.7310265

00:36:30.080 --> 00:36:33.827 Overall response rate of 54 to 62% and

NOTE Confidence: 0.7310265

00:36:33.827 --> 00:36:38.763 then similar trends being seen in CR rates.

NOTE Confidence: 0.7310265

00:36:38.770 --> 00:36:40.680 When they looked at looking

NOTE Confidence: 0.7310265

00:36:40.680 --> 00:36:42.590 here at the waterfall plot,

NOTE Confidence: 0.7310265

00:36:42.590 --> 00:36:45.033 it was seen that all the early

NOTE Confidence: 0.7310265

00:36:45.033 --> 00:36:47.376 dropouts based of you to progression

NOTE Confidence: 0.7310265

00:36:47.376 --> 00:36:50.225 were in the 25 milligram dose cohort,

NOTE Confidence: 0.7310265

00:36:50.230 --> 00:36:53.989 and therefore they did in those expansion

NOTE Confidence: 0.7310265

00:36:53.989 --> 00:36:56.948 phase they decided to go on with.

NOTE Confidence: 0.7310265

00:36:56.950 --> 00:36:59.995 Using a adoes starting with a dose

NOTE Confidence: 0.7310265

00:36:59.995 --> 00:37:03.008 of 75 milligrams vid for two cycles.

NOTE Confidence: 0.7310265

00:37:03.010 --> 00:37:06.034 In those patients who had Disease Control,
NOTE Confidence: 0.7310265

00:37:06.040 --> 00:37:09.412 they would go on to receive
NOTE Confidence: 0.7310265

00:37:09.412 --> 00:37:11.660 25 milligrams pob ID.
NOTE Confidence: 0.7310265

00:37:11.660 --> 00:37:15.965 And now with this combination of doses,
NOTE Confidence: 0.7310265

00:37:15.970 --> 00:37:19.050 an overall response rate of.
NOTE Confidence: 0.8071744

00:37:21.560 --> 00:37:25.128 50% was seen with the CR rate of
NOTE Confidence: 0.8071744

00:37:25.128 --> 00:37:28.366 36% and so there there for this was
NOTE Confidence: 0.8071744

00:37:28.366 --> 00:37:30.950 the overall those expansion phase,
NOTE Confidence: 0.8071744

00:37:30.950 --> 00:37:33.030 including included 25 patients and
NOTE Confidence: 0.8071744

00:37:33.030 --> 00:37:36.139 this is a swimmer plot showing the
NOTE Confidence: 0.8071744

00:37:36.139 --> 00:37:38.989 duration of response for these patients.
NOTE Confidence: 0.8531919

00:37:42.430 --> 00:37:45.316 Again, in terms of side effects,
NOTE Confidence: 0.8531919

00:37:45.320 --> 00:37:48.200 there were no unexpected side effects,
NOTE Confidence: 0.8531919

00:37:48.200 --> 00:37:50.310 and the combination of those
NOTE Confidence: 0.8531919

00:37:50.310 --> 00:37:52.420 where you know those reduction
NOTE Confidence: 0.8531919

00:37:52.494 --> 00:37:55.219 25 milligram was associated with

NOTE Confidence: 0.8531919

00:37:55.219 --> 00:37:56.854 better tolerability overall.

NOTE Confidence: 0.7353012

00:37:58.930 --> 00:38:00.955 So again, this study highlights

NOTE Confidence: 0.7353012

00:38:00.955 --> 00:38:03.442 that develop is definitely an active

NOTE Confidence: 0.7353012

00:38:03.442 --> 00:38:05.776 agent in T cell lymphoma specific,

NOTE Confidence: 0.7353012

00:38:05.780 --> 00:38:08.410 especially in relapsed refractory PTCL.

NOTE Confidence: 0.7353012

00:38:08.410 --> 00:38:11.400 And that this going forward.

NOTE Confidence: 0.7353012

00:38:11.400 --> 00:38:15.320 This study provides data.

NOTE Confidence: 0.7353012

00:38:15.320 --> 00:38:18.728 For using this dual dose of 75 milligram,

NOTE Confidence: 0.7353012

00:38:18.730 --> 00:38:21.510 starting those with 25 milligram.

NOTE Confidence: 0.7353012

00:38:21.510 --> 00:38:25.895 Having a. Efficacy while balancing

NOTE Confidence: 0.7353012

00:38:25.895 --> 00:38:28.925 the toxicity of this single agent.

NOTE Confidence: 0.9055894

00:38:30.950 --> 00:38:35.989 So the last. See the last

NOTE Confidence: 0.9055894

00:38:35.989 --> 00:38:38.154 study in T cell lymphoma.

NOTE Confidence: 0.9055894

00:38:38.160 --> 00:38:41.528 Later, like to highlight is that and this

NOTE Confidence: 0.9055894

00:38:41.528 --> 00:38:45.538 is I'm going to go over this very briefly,

NOTE Confidence: 0.9055894

00:38:45.540 --> 00:38:49.020 but this looked at knew novel
NOTE Confidence: 0.9055894

00:38:49.020 --> 00:38:50.180 Interleukin antagonist.
NOTE Confidence: 0.9055894

00:38:50.180 --> 00:38:52.844 Starting the call going ambition of
NOTE Confidence: 0.9055894

00:38:52.844 --> 00:38:56.500 aisle to aisle 9 and I'll 15 by BNZ 1.
NOTE Confidence: 0.9055894

00:38:56.500 --> 00:38:59.380 And this was studied in a Phase 1
NOTE Confidence: 0.9055894

00:38:59.380 --> 00:39:02.359 two study and it was presented by
NOTE Confidence: 0.9055894

00:39:02.359 --> 00:39:05.040 Doctor Klarfeld from City of Hope.
NOTE Confidence: 0.9055894

00:39:05.040 --> 00:39:07.785 Today study different dose levels
NOTE Confidence: 0.9055894

00:39:07.785 --> 00:39:12.188 and it was those level two of two
NOTE Confidence: 0.9055894

00:39:12.188 --> 00:39:15.821 milligram per kilogram was decided as the.
NOTE Confidence: 0.9055894

00:39:15.830 --> 00:39:18.710 Phase two day for phase two dose based
NOTE Confidence: 0.9055894

00:39:18.710 --> 00:39:21.628 on the PK PD data there there was
NOTE Confidence: 0.9055894

00:39:21.628 --> 00:39:24.586 this drug was not associated with any
NOTE Confidence: 0.9055894

00:39:24.586 --> 00:39:27.514 major side effects and so therefore
NOTE Confidence: 0.9055894

00:39:27.514 --> 00:39:32.245 there was no MTD and based on the.
NOTE Confidence: 0.9055894

00:39:32.250 --> 00:39:33.138 So considering everything,

NOTE Confidence: 0.9055894

00:39:33.138 --> 00:39:34.322 including the efficacy data

NOTE Confidence: 0.9055894

00:39:34.322 --> 00:39:35.370 they discarded around to,

NOTE Confidence: 0.9055894

00:39:35.370 --> 00:39:38.034 go ahead with the dose of

NOTE Confidence: 0.9055894

00:39:38.034 --> 00:39:39.810 2 milligram per kilogram.

NOTE Confidence: 0.9055894

00:39:39.810 --> 00:39:42.794 So this I want to highlight the fact

NOTE Confidence: 0.9055894

00:39:42.794 --> 00:39:46.258 this is was a really highly refractory

NOTE Confidence: 0.9055894

00:39:46.258 --> 00:39:49.439 population of CCL patients with medium

NOTE Confidence: 0.9055894

00:39:49.439 --> 00:39:52.701 file median 5 prior lines of therapy

NOTE Confidence: 0.9055894

00:39:52.701 --> 00:39:55.995 and without any major side effects of

NOTE Confidence: 0.9055894

00:39:55.995 --> 00:39:59.664 an overall response rate of 52% was seen.

NOTE Confidence: 0.9055894

00:39:59.664 --> 00:40:02.526 A subset of patients which is

NOTE Confidence: 0.9055894

00:40:02.526 --> 00:40:05.375 definitely makes this a very promising

NOTE Confidence: 0.9055894

00:40:05.375 --> 00:40:08.081 agent to go further in studies.

NOTE Confidence: 0.9055894

00:40:08.090 --> 00:40:11.548 They do did highlight that you know

NOTE Confidence: 0.9055894

00:40:11.548 --> 00:40:13.803 being targeted blocker of aisle

NOTE Confidence: 0.9055894

00:40:13.803 --> 00:40:15.849 to aisle 15 an aisle 9.
NOTE Confidence: 0.9055894

00:40:15.850 --> 00:40:19.290 It has a 3 prong.
NOTE Confidence: 0.9055894

00:40:19.290 --> 00:40:22.258 I can see where.
NOTE Confidence: 0.9055894

00:40:22.260 --> 00:40:25.460 Including direct anti tumor effect.
NOTE Confidence: 0.9055894

00:40:25.460 --> 00:40:27.962 Reduction of T regs and basically
NOTE Confidence: 0.9055894

00:40:27.962 --> 00:40:30.156 activation of anti tumor immune
NOTE Confidence: 0.9055894

00:40:30.156 --> 00:40:32.832 response and then also an anti
NOTE Confidence: 0.9055894

00:40:32.832 --> 00:40:34.680 inflammatory effect seen through
NOTE Confidence: 0.9055894

00:40:34.680 --> 00:40:37.272 I'll 15 blockade which is relevant
NOTE Confidence: 0.9055894

00:40:37.272 --> 00:40:40.258 for patients with PTCL who have a
NOTE Confidence: 0.9055894

00:40:40.258 --> 00:40:41.946 robust inflammatory reaction that
NOTE Confidence: 0.9055894

00:40:41.946 --> 00:40:44.689 leads to mobility in this disease.
NOTE Confidence: 0.79830873

00:40:47.080 --> 00:40:48.295 So with that,
NOTE Confidence: 0.79830873

00:40:48.295 --> 00:40:50.725 I'd like to quickly shipgirls too,
NOTE Confidence: 0.79830873

00:40:50.730 --> 00:40:53.970 and I will go through this very briefly.
NOTE Confidence: 0.79830873

00:40:53.970 --> 00:40:55.990 A couple of CLL abstracts,

NOTE Confidence: 0.79830873

00:40:55.990 --> 00:40:59.230 so the first one is locked, so 305.

NOTE Confidence: 0.79830873

00:40:59.230 --> 00:41:01.255 This is the next generation,

NOTE Confidence: 0.79830873

00:41:01.260 --> 00:41:04.200 highly selective non covalent BTK inhibitor

NOTE Confidence: 0.79830873

00:41:04.200 --> 00:41:06.760 in previous previously treated CLL SLL.

NOTE Confidence: 0.79830873

00:41:06.760 --> 00:41:09.651 And this was a Phase 1 two

NOTE Confidence: 0.79830873

00:41:09.651 --> 00:41:12.180 study presented by Doctor Matot.

NOTE Confidence: 0.79830873

00:41:12.180 --> 00:41:14.778 So lock the three or five.

NOTE Confidence: 0.79830873

00:41:14.780 --> 00:41:16.864 It's as previously mentioned,

NOTE Confidence: 0.79830873

00:41:16.864 --> 00:41:19.990 the highly selective non covalent BTK

NOTE Confidence: 0.79830873

00:41:20.075 --> 00:41:22.409 inhibitor in it inhibits both wild

NOTE Confidence: 0.79830873

00:41:22.409 --> 00:41:25.369 type as well as C481 mutated BTK.

NOTE Confidence: 0.79830873

00:41:25.370 --> 00:41:27.351 So when we see look at patients

NOTE Confidence: 0.79830873

00:41:27.351 --> 00:41:29.279 who have a BTK resistance,

NOTE Confidence: 0.79830873

00:41:29.280 --> 00:41:31.716 the most common cause of that is

NOTE Confidence: 0.79830873

00:41:31.716 --> 00:41:34.099 because of the mutations in BTK.

NOTE Confidence: 0.79830873

00:41:34.100 --> 00:41:37.190 And this drug does target
NOTE Confidence: 0.79830873

00:41:37.190 --> 00:41:39.662 that population of patients.
NOTE Confidence: 0.79830873

00:41:39.670 --> 00:41:42.652 But this was a these patients
NOTE Confidence: 0.79830873

00:41:42.652 --> 00:41:44.143 were heavily pretreated,
NOTE Confidence: 0.79830873

00:41:44.150 --> 00:41:46.142 including patients who had
NOTE Confidence: 0.79830873

00:41:46.142 --> 00:41:47.636 failed or discontinued,
NOTE Confidence: 0.79830873

00:41:47.640 --> 00:41:50.986 became a better for due to toxicity
NOTE Confidence: 0.79830873

00:41:50.986 --> 00:41:55.010 and also had this is a high risk
NOTE Confidence: 0.79830873

00:41:55.010 --> 00:41:58.098 population of patients with 17 P
NOTE Confidence: 0.79830873

00:41:58.098 --> 00:42:01.086 deletion and TP 53 mutation present
NOTE Confidence: 0.79830873

00:42:01.086 --> 00:42:06.870 present in a total of over 50% of patients.
NOTE Confidence: 0.79830873

00:42:06.870 --> 00:42:09.040 So the Phase one study,
NOTE Confidence: 0.79830873

00:42:09.040 --> 00:42:11.566 so the date data presented is
NOTE Confidence: 0.79830873

00:42:11.566 --> 00:42:14.373 from the Phase one study which
NOTE Confidence: 0.79830873

00:42:14.373 --> 00:42:17.463 included patients with CLL and SLL.
NOTE Confidence: 0.79830873

00:42:17.470 --> 00:42:19.470 And.

NOTE Confidence: 0.79830873

00:42:19.470 --> 00:42:20.110 Uh.

NOTE Confidence: 0.806487

00:42:22.910 --> 00:42:25.568 This loss of three or five

NOTE Confidence: 0.806487

00:42:25.568 --> 00:42:27.340 safety profile was unique,

NOTE Confidence: 0.806487

00:42:27.340 --> 00:42:31.732 as in the the most common grade three side

NOTE Confidence: 0.806487

00:42:31.732 --> 00:42:36.007 effect was actually fatigue and the typical.

NOTE Confidence: 0.806487

00:42:36.010 --> 00:42:39.844 Side effects associated with other BTK

NOTE Confidence: 0.806487

00:42:39.844 --> 00:42:42.400 innovators like atrial fibrillation.

NOTE Confidence: 0.806487

00:42:42.400 --> 00:42:44.866 The side effects were not very

NOTE Confidence: 0.806487

00:42:44.866 --> 00:42:47.510 prominent with locks or two or five.

NOTE Confidence: 0.806487

00:42:47.510 --> 00:42:49.470 Since there was no DLT's,

NOTE Confidence: 0.806487

00:42:49.470 --> 00:42:52.200 the maximum tolerated dose was not reached,

NOTE Confidence: 0.806487

00:42:52.200 --> 00:42:57.182 and. Based on the PK data and the efficacy

NOTE Confidence: 0.806487

00:42:57.182 --> 00:43:00.235 data dose of 200 milligrams was decided

NOTE Confidence: 0.806487

00:43:00.235 --> 00:43:02.950 as the recommended phase two dose.

NOTE Confidence: 0.806487

00:43:02.950 --> 00:43:05.477 Again, here it was in a heavily

NOTE Confidence: 0.806487

00:43:05.477 --> 00:43:06.560 pretreated well population.
NOTE Confidence: 0.806487

00:43:06.560 --> 00:43:11.078 Locks or three or five was found to be.
NOTE Confidence: 0.806487

00:43:11.080 --> 00:43:13.399 Continue to have.
NOTE Confidence: 0.806487

00:43:13.400 --> 00:43:17.000 Made up a very good efficacy in this.
NOTE Confidence: 0.806487

00:43:17.000 --> 00:43:21.592 Beta in this patient population and looking
NOTE Confidence: 0.806487

00:43:21.592 --> 00:43:26.050 at the overall response rate of 63%.
NOTE Confidence: 0.806487

00:43:26.050 --> 00:43:27.652 So it was.
NOTE Confidence: 0.806487

00:43:27.652 --> 00:43:29.788 It was a very.
NOTE Confidence: 0.806487

00:43:29.790 --> 00:43:31.395 Good basically good response in
NOTE Confidence: 0.806487

00:43:31.395 --> 00:43:33.502 this without a lot of toxicity
NOTE Confidence: 0.806487

00:43:33.502 --> 00:43:35.246 in this patient population.
NOTE Confidence: 0.77512187

00:43:37.660 --> 00:43:39.991 So lots of three or five was
NOTE Confidence: 0.77512187

00:43:39.991 --> 00:43:42.109 active at all those levels,
NOTE Confidence: 0.77512187

00:43:42.110 --> 00:43:44.324 and typical became a bitter or
NOTE Confidence: 0.77512187

00:43:44.324 --> 00:43:46.190 related toxicities were not seen.
NOTE Confidence: 0.77512187

00:43:46.190 --> 00:43:47.702 These responses were independent,

NOTE Confidence: 0.77512187

00:43:47.702 --> 00:43:49.970 BTK mutation and even patients who

NOTE Confidence: 0.77512187

00:43:50.033 --> 00:43:51.758 had received BCL two inhibitor.

NOTE Confidence: 0.77512187

00:43:51.760 --> 00:43:54.357 When I took LAX as well as

NOTE Confidence: 0.77512187

00:43:54.357 --> 00:43:55.470 three kinase inhibitors,

NOTE Confidence: 0.77512187

00:43:55.470 --> 00:43:57.320 did respond to this drug.

NOTE Confidence: 0.77512187

00:43:57.320 --> 00:43:59.175 So there's a safety and

NOTE Confidence: 0.77512187

00:43:59.175 --> 00:44:00.659 efficacy signal in CLL.

NOTE Confidence: 0.77512187

00:44:00.660 --> 00:44:03.294 Yeliz will be passed participating in

NOTE Confidence: 0.77512187

00:44:03.294 --> 00:44:06.100 the phase two portion of this data.

NOTE Confidence: 0.77512187

00:44:06.100 --> 00:44:06.949 Of this study.

NOTE Confidence: 0.725289520333333

00:44:09.050 --> 00:44:12.242 Um? And then finally I just want to

NOTE Confidence: 0.725289520333333

00:44:12.242 --> 00:44:14.375 mention this particular study that

NOTE Confidence: 0.725289520333333

00:44:14.375 --> 00:44:17.811 was open at Yale in the past and

NOTE Confidence: 0.725289520333333

00:44:17.811 --> 00:44:20.457 that is umbrella civs and you've

NOTE Confidence: 0.725289520333333

00:44:20.457 --> 00:44:22.968 lytic seemab you two study which

NOTE Confidence: 0.725289520333333

00:44:22.968 --> 00:44:25.344 used a novel dual inhibitor ,
NOTE Confidence: 0.725289520333333

00:44:25.350 --> 00:44:27.320 three kinase and casein kind
NOTE Confidence: 0.725289520333333

00:44:27.320 --> 00:44:29.700 is money in a better and.
NOTE Confidence: 0.8235949

00:44:31.770 --> 00:44:34.269 The only issues with this study was
NOTE Confidence: 0.8235949

00:44:34.269 --> 00:44:36.527 that you know the comparator arm
NOTE Confidence: 0.8235949

00:44:36.527 --> 00:44:39.124 was a bit as a map chlorambucil,
NOTE Confidence: 0.8235949

00:44:39.130 --> 00:44:41.356 which is not really a very
NOTE Confidence: 0.8235949

00:44:41.356 --> 00:44:43.549 relevant in this day and age,
NOTE Confidence: 0.8235949

00:44:43.550 --> 00:44:45.746 at least for treatment naive patients.
NOTE Confidence: 0.8235949

00:44:45.750 --> 00:44:47.622 But this is being studied further
NOTE Confidence: 0.8235949

00:44:47.622 --> 00:44:49.396 in combination both in frontline
NOTE Confidence: 0.8235949

00:44:49.396 --> 00:44:51.268 and relapsed refractory setting.
NOTE Confidence: 0.8955445

00:44:53.740 --> 00:44:54.560 That's all I have.
NOTE Confidence: 0.82034147

00:45:15.680 --> 00:45:16.550 Tell everybody.
NOTE Confidence: 0.76212716

00:45:27.840 --> 00:45:32.224 Hello everybody, I'm going to go over the.
NOTE Confidence: 0.76212716

00:45:32.230 --> 00:45:34.556 Abstract relevant to heart killing

NOTE Confidence: 0.76212716

00:45:34.556 --> 00:45:38.004 form for the sake of time I'll

NOTE Confidence: 0.76212716

00:45:38.004 --> 00:45:41.357 try to be brief and uncover only

NOTE Confidence: 0.76212716

00:45:41.357 --> 00:45:44.097 heart killing form at this time.

NOTE Confidence: 0.76212716

00:45:44.100 --> 00:45:46.858 So since the introduction of Brentuximab and

NOTE Confidence: 0.76212716

00:45:46.858 --> 00:45:49.458 Odin and checkpoint inhibitors in general,

NOTE Confidence: 0.76212716

00:45:49.460 --> 00:45:51.932 the paradigm of treatment for this

NOTE Confidence: 0.76212716

00:45:51.932 --> 00:45:53.990 disease is changed substantially, and.

NOTE Confidence: 0.8009456

00:45:56.970 --> 00:45:58.035 And this agent,

NOTE Confidence: 0.8009456

00:45:58.035 --> 00:46:00.520 that now you been used earlier and

NOTE Confidence: 0.8009456

00:46:00.598 --> 00:46:03.230 earlier in the course of the disease.

NOTE Confidence: 0.8009456

00:46:03.230 --> 00:46:05.426 So I will review the knew,

NOTE Confidence: 0.8009456

00:46:05.430 --> 00:46:07.600 the updates and the new data relevant

NOTE Confidence: 0.8009456

00:46:07.600 --> 00:46:09.915 of the uses regarding the using of

NOTE Confidence: 0.8009456

00:46:09.915 --> 00:46:12.465 these agents in first line in the

NOTE Confidence: 0.8009456

00:46:12.465 --> 00:46:15.000 relapsed refractory setting and maintenance.

NOTE Confidence: 0.8009456

00:46:15.000 --> 00:46:16.824 Adding after transplant and
NOTE Confidence: 0.8009456

00:46:16.824 --> 00:46:18.648 in the elderly population.
NOTE Confidence: 0.8009456

00:46:18.650 --> 00:46:20.140 So let's start with that.
NOTE Confidence: 0.8009456

00:46:20.140 --> 00:46:22.516 The five year update of action on one,
NOTE Confidence: 0.8009456

00:46:22.520 --> 00:46:25.838 as we all know, this is a.
NOTE Confidence: 0.8009456

00:46:25.840 --> 00:46:27.950 A very large open label,
NOTE Confidence: 0.8009456

00:46:27.950 --> 00:46:29.516 multicenter randomized phase.
NOTE Confidence: 0.8009456

00:46:29.516 --> 00:46:32.648 Three study that was initially presented
NOTE Confidence: 0.8009456

00:46:32.648 --> 00:46:35.392 at three years ago at the Ash meeting
NOTE Confidence: 0.8009456

00:46:35.392 --> 00:46:38.500 with a 2 year follow up over 1300
NOTE Confidence: 0.8009456

00:46:38.500 --> 00:46:41.032 patients were randomized either to get
NOTE Confidence: 0.8009456

00:46:41.032 --> 00:46:43.986 brentuximab avd for six cycles or abvd,
NOTE Confidence: 0.8009456

00:46:43.990 --> 00:46:46.510 which is the standard treatment at
NOTE Confidence: 0.8009456

00:46:46.510 --> 00:46:49.050 city was performed after two cycles,
NOTE Confidence: 0.8009456

00:46:49.050 --> 00:46:52.426 but this was not a pet adapted approach.
NOTE Confidence: 0.8009456

00:46:52.430 --> 00:46:55.030 The primary endpoint of the

NOTE Confidence: 0.8009456

00:46:55.030 --> 00:46:57.630 study was a modified PFS.

NOTE Confidence: 0.8009456

00:46:57.630 --> 00:47:00.045 Which is which included time to progression

NOTE Confidence: 0.8009456

00:47:00.045 --> 00:47:02.110 that and not completely response

NOTE Confidence: 0.8009456

00:47:02.110 --> 00:47:04.530 and use of subsequent chemotherapy.

NOTE Confidence: 0.8009456

00:47:04.530 --> 00:47:07.050 This modified PFS was meant to capture

NOTE Confidence: 0.8009456

00:47:07.050 --> 00:47:09.974 all the events that reflected the failure

NOTE Confidence: 0.8009456

00:47:09.974 --> 00:47:12.184 of frontline treatment and patient

NOTE Confidence: 0.8009456

00:47:12.184 --> 00:47:15.485 and were followed up with the serial imaging.

NOTE Confidence: 0.8009456

00:47:15.490 --> 00:47:18.584 The first data set that was presented

NOTE Confidence: 0.8009456

00:47:18.584 --> 00:47:21.697 from this dialogue after a follow up

NOTE Confidence: 0.8009456

00:47:21.697 --> 00:47:24.253 Papa to essentially two years showed

NOTE Confidence: 0.8009456

00:47:24.338 --> 00:47:27.335 a benefit in using a plus abvd A plus.

NOTE Confidence: 0.8009456

00:47:27.340 --> 00:47:30.854 Abd compared to a DVD with an

NOTE Confidence: 0.8009456

00:47:30.854 --> 00:47:33.079 absolute in benefit of 5%,

NOTE Confidence: 0.8009456

00:47:33.080 --> 00:47:34.988 this modified progression free

NOTE Confidence: 0.8009456

00:47:34.988 --> 00:47:37.373 survival was 82 versus 77.
NOTE Confidence: 0.8009456

00:47:37.380 --> 00:47:40.523 This came at the cost of significant
NOTE Confidence: 0.8009456

00:47:40.523 --> 00:47:42.640 increase in side effects.
NOTE Confidence: 0.8009456

00:47:42.640 --> 00:47:45.496 Neutropenia 58% versus 45 from Europe.
NOTE Confidence: 0.8009456

00:47:45.500 --> 00:47:48.846 But there was a big big one
NOTE Confidence: 0.8009456

00:47:48.846 --> 00:47:50.827 with a 67% incidents.
NOTE Confidence: 0.8009456

00:47:50.827 --> 00:47:54.656 An informercial city was the one that
NOTE Confidence: 0.8009456

00:47:54.656 --> 00:47:58.306 was reduced due to the omission of the.
NOTE Confidence: 0.8009456

00:47:58.310 --> 00:47:58.791 Bleomycin.
NOTE Confidence: 0.8009456

00:47:58.791 --> 00:48:02.158 So why this is the five year
NOTE Confidence: 0.8009456

00:48:02.158 --> 00:48:05.189 five year update is important.
NOTE Confidence: 0.8009456

00:48:05.190 --> 00:48:07.686 We nearly all recurrences of Hodgkin
NOTE Confidence: 0.8009456

00:48:07.686 --> 00:48:10.100 lymphoma happen usually within five years,
NOTE Confidence: 0.8009456

00:48:10.100 --> 00:48:13.036 so we think that PFS of five year
NOTE Confidence: 0.8009456

00:48:13.036 --> 00:48:16.233 is a good surrogate for for cure
NOTE Confidence: 0.8009456

00:48:16.233 --> 00:48:19.433 an here the five year data we

NOTE Confidence: 0.8009456

00:48:19.433 --> 00:48:22.369 do see the PFS for the A plus.

NOTE Confidence: 0.8009456

00:48:22.370 --> 00:48:25.636 Avd is the red curve 82% of five

NOTE Confidence: 0.8009456

00:48:25.636 --> 00:48:28.150 years compared to 75% in the

NOTE Confidence: 0.8009456

00:48:28.150 --> 00:48:30.350 ABVD Ann and these disadvantage.

NOTE Confidence: 0.8009456

00:48:30.350 --> 00:48:32.320 And that was observed initially

NOTE Confidence: 0.8009456

00:48:32.320 --> 00:48:33.896 persisted overtime maybe depend.

NOTE Confidence: 0.8009456

00:48:33.900 --> 00:48:36.518 And this was how they threw in

NOTE Confidence: 0.8009456

00:48:36.518 --> 00:48:38.535 in patients achieving the path

NOTE Confidence: 0.8009456

00:48:38.535 --> 00:48:40.590 to negativity after two cycles.

NOTE Confidence: 0.8009456

00:48:40.590 --> 00:48:43.958 This hopper curb is 2 cars here compared

NOTE Confidence: 0.8009456

00:48:43.958 --> 00:48:46.788 to those that were at negative.

NOTE Confidence: 0.8009456

00:48:46.790 --> 00:48:49.838 So this was not a fat adapted approach.

NOTE Confidence: 0.8009456

00:48:49.840 --> 00:48:50.196 Again,

NOTE Confidence: 0.8009456

00:48:50.196 --> 00:48:52.688 the rates of if you remember the

NOTE Confidence: 0.8009456

00:48:52.688 --> 00:48:54.788 data from this work started.

NOTE Confidence: 0.8009456

00:48:54.790 --> 00:48:55.143 Yes,
NOTE Confidence: 0.8009456

00:48:55.143 --> 00:48:57.261 816 trial where patients had positive
NOTE Confidence: 0.8009456

00:48:57.261 --> 00:48:59.595 after two cycles received ended up
NOTE Confidence: 0.8009456

00:48:59.595 --> 00:49:02.025 receiving escalated Beacopp for six cycles.
NOTE Confidence: 0.8009456

00:49:02.030 --> 00:49:03.875 This PFS compared favorably to
NOTE Confidence: 0.8009456

00:49:03.875 --> 00:49:06.123 patients that received and much more
NOTE Confidence: 0.8009456

00:49:06.123 --> 00:49:08.157 aggressive course of treatment with a
NOTE Confidence: 0.8009456

00:49:08.157 --> 00:49:10.789 very high rate of secondary malignancies,
NOTE Confidence: 0.8009456

00:49:10.790 --> 00:49:13.076 and based on the profile and
NOTE Confidence: 0.8009456

00:49:13.076 --> 00:49:14.219 different risk characteristics.
NOTE Confidence: 0.8009456

00:49:14.220 --> 00:49:17.340 Applications are in the trial.
NOTE Confidence: 0.8009456

00:49:17.340 --> 00:49:20.042 Or the essentially all the group favored
NOTE Confidence: 0.8009456

00:49:20.042 --> 00:49:22.869 the use of brentuximab plus avd.
NOTE Confidence: 0.8009456

00:49:22.870 --> 00:49:25.166 So I think that was a highlighted
NOTE Confidence: 0.8009456

00:49:25.166 --> 00:49:26.150 and I think
NOTE Confidence: 0.8391127

00:49:26.226 --> 00:49:28.938 it's very important to note is

NOTE Confidence: 0.8391127

00:49:28.938 --> 00:49:30.746 that the peripheral neuropathy,

NOTE Confidence: 0.8391127

00:49:30.750 --> 00:49:33.494 which was one of the concern major concern

NOTE Confidence: 0.8391127

00:49:33.494 --> 00:49:36.270 when the initial results were released,

NOTE Confidence: 0.8391127

00:49:36.270 --> 00:49:38.240 has really improved or complete.

NOTE Confidence: 0.8391127

00:49:38.240 --> 00:49:41.691 Completely resolved in the vast majority of

NOTE Confidence: 0.8391127

00:49:41.691 --> 00:49:45.347 the patient and with an improvement that.

NOTE Confidence: 0.8391127

00:49:45.350 --> 00:49:46.726 Happened progressively over the

NOTE Confidence: 0.8391127

00:49:46.726 --> 00:49:48.790 course of the years and currently

NOTE Confidence: 0.8391127

00:49:48.844 --> 00:49:50.220 patients will receive one.

NOTE Confidence: 0.8391127

00:49:50.220 --> 00:49:52.308 Prefer neuropathy, have a really low

NOTE Confidence: 0.8391127

00:49:52.308 --> 00:49:54.338 grade of peripheral neuropathy, if any.

NOTE Confidence: 0.8391127

00:49:54.338 --> 00:49:56.252 Another thing that was noted in

NOTE Confidence: 0.8391127

00:49:56.252 --> 00:49:58.498 this five year update is that

NOTE Confidence: 0.8391127

00:49:58.498 --> 00:50:00.418 the rate of secondary malignancy.

NOTE Confidence: 0.8391127

00:50:00.420 --> 00:50:02.555 And the rate of successful

NOTE Confidence: 0.8391127

00:50:02.555 --> 00:50:05.130 pregnancies compared well to the ABVD.

NOTE Confidence: 0.8391127

00:50:05.130 --> 00:50:07.826 Um, so I think that with this five

NOTE Confidence: 0.8391127

00:50:07.826 --> 00:50:10.187 year update of the action and one,

NOTE Confidence: 0.8391127

00:50:10.190 --> 00:50:12.818 we have more compelling.

NOTE Confidence: 0.8391127

00:50:12.820 --> 00:50:16.308 Data now to support the use of this.

NOTE Confidence: 0.8391127

00:50:16.310 --> 00:50:18.524 Judgment and more widely in the

NOTE Confidence: 0.8391127

00:50:18.524 --> 00:50:20.889 in the upfront setting in hybrids

NOTE Confidence: 0.8391127

00:50:20.889 --> 00:50:22.670 in untreated stage, 4,

NOTE Confidence: 0.8391127

00:50:22.670 --> 00:50:25.201 three and four patients. Um,

NOTE Confidence: 0.8391127

00:50:25.201 --> 00:50:27.849 I just want to briefly briefly mention this.

NOTE Confidence: 0.8391127

00:50:27.850 --> 00:50:28.628 This trial,

NOTE Confidence: 0.8391127

00:50:28.628 --> 00:50:31.351 which was presented as a post office

NOTE Confidence: 0.8391127

00:50:31.351 --> 00:50:34.195 there is more that concept that was

NOTE Confidence: 0.8391127

00:50:34.195 --> 00:50:36.524 presented because this is an ongoing

NOTE Confidence: 0.8391127

00:50:36.524 --> 00:50:39.180 trial and we're part of it at Yale.

NOTE Confidence: 0.8391127

00:50:39.180 --> 00:50:42.351 He said as we just reviewed the

NOTE Confidence: 0.8391127

00:50:42.351 --> 00:50:44.673 addition of brentuximab window tint

NOTE Confidence: 0.8391127

00:50:44.673 --> 00:50:47.746 to avd improves PFS in advanced age,

NOTE Confidence: 0.8391127

00:50:47.750 --> 00:50:51.320 but still 15 to 20% patients are relapse,

NOTE Confidence: 0.8391127

00:50:51.320 --> 00:50:53.520 relapse or refractory and BV

NOTE Confidence: 0.8391127

00:50:53.520 --> 00:50:55.389 addition increases toxicity and

NOTE Confidence: 0.8391127

00:50:55.389 --> 00:50:56.766 require growth factors.

NOTE Confidence: 0.8391127

00:50:56.770 --> 00:51:02.106 So this is the this is the largest.

NOTE Confidence: 0.8391127

00:51:02.110 --> 00:51:04.454 North American Cooperative group

NOTE Confidence: 0.8391127

00:51:04.454 --> 00:51:07.970 trials in Advanced Hodgkin study that

NOTE Confidence: 0.8391127

00:51:08.054 --> 00:51:10.604 is being conducted in collaboration

NOTE Confidence: 0.8391127

00:51:10.604 --> 00:51:13.813 with Canada and even with the

NOTE Confidence: 0.8391127

00:51:13.813 --> 00:51:16.089 collaboration of the children.

NOTE Confidence: 0.8391127

00:51:16.090 --> 00:51:18.770 The theology.

NOTE Confidence: 0.8391127

00:51:18.770 --> 00:51:21.212 Patrick Oncology group for Hodgkin is

NOTE Confidence: 0.8391127

00:51:21.212 --> 00:51:24.346 a study that is planning to enroll

NOTE Confidence: 0.8391127

00:51:24.346 --> 00:51:26.726 987 patients and two randomized
NOTE Confidence: 0.8391127

00:51:26.726 --> 00:51:29.478 them either to nivolumab avd versus
NOTE Confidence: 0.8391127

00:51:29.478 --> 00:51:32.912 Brentuximab and Odin and Avd for six cycles.
NOTE Confidence: 0.8391127

00:51:32.912 --> 00:51:35.894 The patients are going to be satisfied
NOTE Confidence: 0.8391127

00:51:35.894 --> 00:51:38.640 based on the age Ipsy and intended
NOTE Confidence: 0.8391127

00:51:38.640 --> 00:51:41.299 use of radiation and the primary
NOTE Confidence: 0.8391127

00:51:41.299 --> 00:51:44.019 endpoint is progression free survival,
NOTE Confidence: 0.8391127

00:51:44.020 --> 00:51:47.300 but a lot of other data are planned
NOTE Confidence: 0.8391127

00:51:47.300 --> 00:51:49.130 to be gathered.
NOTE Confidence: 0.8391127

00:51:49.130 --> 00:51:50.300 And in particular,
NOTE Confidence: 0.8391127

00:51:50.300 --> 00:51:52.250 patient reported outcomes including fatigue,
NOTE Confidence: 0.8391127

00:51:52.250 --> 00:51:54.590 neuropathy, scoring and quality of life.
NOTE Confidence: 0.8391127

00:51:54.590 --> 00:51:55.760 So despite covid,
NOTE Confidence: 0.8391127

00:51:55.760 --> 00:51:57.710 it looks like the TARDIS.
NOTE Confidence: 0.8391127

00:51:57.710 --> 00:52:00.670 This trial is at the target of the
NOTE Confidence: 0.8391127

00:52:00.670 --> 00:52:02.697 expected accrual and the results

NOTE Confidence: 0.8391127

00:52:02.697 --> 00:52:05.115 of this trial are eagerly awaited.

NOTE Confidence: 0.8391127

00:52:05.120 --> 00:52:08.240 So let's move them to the salvage treatment.

NOTE Confidence: 0.8391127

00:52:08.240 --> 00:52:10.580 What's new in the salvage treatment?

NOTE Confidence: 0.8391127

00:52:10.580 --> 00:52:13.112 So usually provision that are relapsed

NOTE Confidence: 0.8391127

00:52:13.112 --> 00:52:15.589 refractory after the first line of

NOTE Confidence: 0.8391127

00:52:15.589 --> 00:52:17.731 treatment of the general approach is

NOTE Confidence: 0.8391127

00:52:17.731 --> 00:52:20.078 to proceed to salvage chemotherapy.

NOTE Confidence: 0.8391127

00:52:20.080 --> 00:52:22.355 Usually platinum based or genocide

NOTE Confidence: 0.8391127

00:52:22.355 --> 00:52:24.630 happen based with an expected

NOTE Confidence: 0.8391127

00:52:24.709 --> 00:52:27.392 response rate in the 50-60% range with

NOTE Confidence: 0.8391127

00:52:27.392 --> 00:52:29.056 introduction of brentuximab concurrently

NOTE Confidence: 0.8391127

00:52:29.056 --> 00:52:31.739 or sequentially in the salvage regiment,

NOTE Confidence: 0.8391127

00:52:31.740 --> 00:52:34.332 we now expect responses in the

NOTE Confidence: 0.8391127

00:52:34.332 --> 00:52:35.984 60 and 70% range,

NOTE Confidence: 0.8391127

00:52:35.984 --> 00:52:39.170 but the use of a print aksamit now is

NOTE Confidence: 0.8391127

00:52:39.252 --> 00:52:42.178 getting limited by the fact that is
NOTE Confidence: 0.8391127

00:52:42.178 --> 00:52:45.547 used more widely in the first line
NOTE Confidence: 0.8391127

00:52:45.547 --> 00:52:47.575 and therefore alternative strategies
NOTE Confidence: 0.8391127

00:52:47.575 --> 00:52:50.960 that are being explored in this study.
NOTE Confidence: 0.8391127

00:52:50.960 --> 00:52:51.365 Specifically,
NOTE Confidence: 0.8391127

00:52:51.365 --> 00:52:54.200 is a face to study using bumper
NOTE Confidence: 0.8391127

00:52:54.200 --> 00:52:56.987 lizama in addition to our regular
NOTE Confidence: 0.8391127

00:52:56.987 --> 00:52:58.409 salvage treatment GD,
NOTE Confidence: 0.8391127

00:52:58.410 --> 00:53:00.738 which is one of the historically
NOTE Confidence: 0.8391127

00:53:00.738 --> 00:53:02.290 used salvage treatment as
NOTE Confidence: 0.7681064

00:53:02.360 --> 00:53:05.168 a second line for relapsed refractory
NOTE Confidence: 0.7681064

00:53:05.168 --> 00:53:07.040 article informal and eligibility
NOTE Confidence: 0.7681064

00:53:07.112 --> 00:53:09.788 dissipation that our love story factory.
NOTE Confidence: 0.7681064

00:53:09.790 --> 00:53:11.980 The first line of treatment.
NOTE Confidence: 0.7681064

00:53:11.980 --> 00:53:14.518 Primary endpoint is the PCR rate
NOTE Confidence: 0.7681064

00:53:14.518 --> 00:53:16.702 because that's the most important

NOTE Confidence: 0.7681064

00:53:16.702 --> 00:53:19.558 factor that we that we have to

NOTE Confidence: 0.7681064

00:53:19.558 --> 00:53:21.820 achieve after salvage treatment.

NOTE Confidence: 0.7681064

00:53:21.820 --> 00:53:24.658 With Adima to pursue to transplant.

NOTE Confidence: 0.7681064

00:53:24.660 --> 00:53:27.780 So patients received the regular GBD

NOTE Confidence: 0.7681064

00:53:27.780 --> 00:53:31.202 combination and they want and they ate

NOTE Confidence: 0.7681064

00:53:31.202 --> 00:53:34.135 with addition of populism on day one.

NOTE Confidence: 0.7681064

00:53:34.140 --> 00:53:36.510 After two cycles of patients

NOTE Confidence: 0.7681064

00:53:36.510 --> 00:53:38.406 but positive patient back,

NOTE Confidence: 0.7681064

00:53:38.410 --> 00:53:40.302 negative were allowed to

NOTE Confidence: 0.7681064

00:53:40.302 --> 00:53:42.194 pursue directly to transplant.

NOTE Confidence: 0.7681064

00:53:42.200 --> 00:53:44.845 Otherwise everybody received 4 cycle

NOTE Confidence: 0.7681064

00:53:44.845 --> 00:53:49.010 and then that was evaluated at the end

NOTE Confidence: 0.7681064

00:53:49.010 --> 00:53:51.390 of treatment before the transplant.

NOTE Confidence: 0.7681064

00:53:51.390 --> 00:53:53.050 So let's see what happened.

NOTE Confidence: 0.7681064

00:53:53.050 --> 00:53:55.374 There were 939 patients enrolled in this

NOTE Confidence: 0.7681064

00:53:55.374 --> 00:53:58.027 study, with a median age of 38 years.
NOTE Confidence: 0.7681064

00:53:58.030 --> 00:53:58.344 Importantly,
NOTE Confidence: 0.7681064

00:53:58.344 --> 00:54:00.228 most of the patients were advanced
NOTE Confidence: 0.7681064

00:54:00.228 --> 00:54:01.926 age of the initial diagnosis
NOTE Confidence: 0.7681064

00:54:01.926 --> 00:54:03.666 and the time of enrollment.
NOTE Confidence: 0.7681064

00:54:03.670 --> 00:54:04.666 When they relapsed,
NOTE Confidence: 0.7681064

00:54:04.666 --> 00:54:06.326 many patients had extranodal site,
NOTE Confidence: 0.7681064

00:54:06.330 --> 00:54:07.990 1/3 of them extranodal sites
NOTE Confidence: 0.7681064

00:54:07.990 --> 00:54:08.986 of disease involvement,
NOTE Confidence: 0.7681064

00:54:08.990 --> 00:54:10.645 and the symptoms was present
NOTE Confidence: 0.7681064

00:54:10.645 --> 00:54:13.908 in 15% of the patient.
NOTE Confidence: 0.7681064

00:54:13.910 --> 00:54:15.985 Almost like 40% were refractory
NOTE Confidence: 0.7681064

00:54:15.985 --> 00:54:18.528 or either they relapsed in first
NOTE Confidence: 0.7681064

00:54:18.528 --> 00:54:20.886 year so very high risk patient
NOTE Confidence: 0.7681064

00:54:20.886 --> 00:54:23.076 population and the treatment they
NOTE Confidence: 0.7681064

00:54:23.076 --> 00:54:25.866 received up front was primarily ABVD,

NOTE Confidence: 0.7681064

00:54:25.870 --> 00:54:28.300 but some patients reserved receive the

NOTE Confidence: 0.7681064

00:54:28.300 --> 00:54:31.419 print axiom an and or Veeco approaches.

NOTE Confidence: 0.7681064

00:54:31.420 --> 00:54:33.982 So after the first 2 cycles

NOTE Confidence: 0.7681064

00:54:33.982 --> 00:54:36.544 of pembrolizumab T 92% of the

NOTE Confidence: 0.7681064

00:54:36.544 --> 00:54:39.960 patients were found to be in a CR,

NOTE Confidence: 0.7681064

00:54:39.960 --> 00:54:41.940 and that's unprecedented data

NOTE Confidence: 0.7681064

00:54:41.940 --> 00:54:43.920 for a salvage attachment.

NOTE Confidence: 0.7681064

00:54:43.920 --> 00:54:46.517 And after an additional 2 cycles and

NOTE Confidence: 0.7681064

00:54:46.517 --> 00:54:49.150 there was an additional CR rate,

NOTE Confidence: 0.7681064

00:54:49.150 --> 00:54:51.966 so the total see CR rate for this

NOTE Confidence: 0.7681064

00:54:51.966 --> 00:54:54.769 group of patients was 95 percent,

NOTE Confidence: 0.7681064

00:54:54.770 --> 00:54:57.128 95% proceeding to transplant and a

NOTE Confidence: 0.7681064

00:54:57.128 --> 00:55:00.062 good amount about a third of them

NOTE Confidence: 0.7681064

00:55:00.062 --> 00:55:02.207 preceded to maintenance with the

NOTE Confidence: 0.7681064

00:55:02.207 --> 00:55:04.820 print accent windowed in for a year.

NOTE Confidence: 0.7681064

00:55:04.820 --> 00:55:07.238 Based on the accurate trial study,
NOTE Confidence: 0.7681064

00:55:07.240 --> 00:55:09.963 an none of the patient with limited
NOTE Confidence: 0.7681064

00:55:09.963 --> 00:55:13.282 follow up that we have now for this
NOTE Confidence: 0.7681064

00:55:13.282 --> 00:55:15.347 study at progression of disease.
NOTE Confidence: 0.7681064

00:55:15.350 --> 00:55:18.017 After the transplant. So why this this?
NOTE Confidence: 0.7681064

00:55:18.020 --> 00:55:19.930 This regiment works so well.
NOTE Confidence: 0.7681064

00:55:19.930 --> 00:55:21.860 It even outperformed what checkpoint
NOTE Confidence: 0.7681064

00:55:21.860 --> 00:55:24.140 plus chemotherapy does in first line.
NOTE Confidence: 0.7681064

00:55:24.140 --> 00:55:26.884 Sony Vollmer Avd does not have the
NOTE Confidence: 0.7681064

00:55:26.884 --> 00:55:29.672 same efficacy and one of the reasons
NOTE Confidence: 0.7681064

00:55:29.672 --> 00:55:31.976 that the others are looking into
NOTE Confidence: 0.7681064

00:55:32.056 --> 00:55:34.534 is if there is anything specific in
NOTE Confidence: 0.7681064

00:55:34.534 --> 00:55:37.032 this may be the synergy between the
NOTE Confidence: 0.7681064

00:55:37.032 --> 00:55:39.180 chemotherapy agent that is unique to
NOTE Confidence: 0.7681064

00:55:39.249 --> 00:55:41.678 this regiment inside I mean with a
NOTE Confidence: 0.7681064

00:55:41.678 --> 00:55:43.257 checkpoint inhibitor in particular

NOTE Confidence: 0.7681064

00:55:43.257 --> 00:55:45.647 the ability of selectively eliminate.

NOTE Confidence: 0.7681064

00:55:45.650 --> 00:55:48.188 That my little derived suppressor cells,

NOTE Confidence: 0.7681064

00:55:48.190 --> 00:55:50.788 so these exciting results poised base

NOTE Confidence: 0.7681064

00:55:50.788 --> 00:55:53.688 for the next court on this study,

NOTE Confidence: 0.7681064

00:55:53.690 --> 00:55:56.728 were actually the aim is to treat

NOTE Confidence: 0.7681064

00:55:56.728 --> 00:55:59.607 everybody with Pembridge EBD for four cycles,

NOTE Confidence: 0.7681064

00:55:59.610 --> 00:56:01.980 and then skip the Trump's transplant

NOTE Confidence: 0.7681064

00:56:01.980 --> 00:56:04.690 altogether and have the patient instead.

NOTE Confidence: 0.7681064

00:56:04.690 --> 00:56:07.222 Being on maintenance with 13 cycles

NOTE Confidence: 0.7681064

00:56:07.222 --> 00:56:08.488 of pembrolizumab maintenance.

NOTE Confidence: 0.7681064

00:56:08.490 --> 00:56:12.765 So this is going to be very exciting to

NOTE Confidence: 0.7681064

00:56:12.765 --> 00:56:17.340 see what the outcome of this patient is.

NOTE Confidence: 0.7681064

00:56:17.340 --> 00:56:18.064 Moving forward,

NOTE Confidence: 0.7681064

00:56:18.064 --> 00:56:19.874 let's talk about consolidation after

NOTE Confidence: 0.7681064

00:56:19.874 --> 00:56:21.392 transplant. What's new in that?

NOTE Confidence: 0.7681064

00:56:21.392 --> 00:56:23.556 We know that patients at high risk
NOTE Confidence: 0.7681064

00:56:23.556 --> 00:56:25.436 of relapse after the transplant
NOTE Confidence: 0.7681064

00:56:25.436 --> 00:56:27.531 based on the characteristic primary
NOTE Confidence: 0.7681064

00:56:27.531 --> 00:56:28.589 refractory disease.
NOTE Confidence: 0.7681064

00:56:28.590 --> 00:56:30.485 As general involvement with symptoms
NOTE Confidence: 0.7681064

00:56:30.485 --> 00:56:32.380 of relapse order requiring more
NOTE Confidence: 0.7941296

00:56:32.445 --> 00:56:34.395 than one line of salvage treatment,
NOTE Confidence: 0.7941296

00:56:34.400 --> 00:56:36.934 not in CR, the time of transplant,
NOTE Confidence: 0.7941296

00:56:36.940 --> 00:56:38.755 they are higher risk of
NOTE Confidence: 0.7941296

00:56:38.755 --> 00:56:39.844 relapsing after transplant.
NOTE Confidence: 0.7941296

00:56:39.850 --> 00:56:42.154 So now there have been strategies
NOTE Confidence: 0.7941296

00:56:42.154 --> 00:56:44.095 that have been explored that
NOTE Confidence: 0.7941296

00:56:44.095 --> 00:56:45.780 to improve their PFS and.
NOTE Confidence: 0.7941296

00:56:45.780 --> 00:56:48.284 We all know about the if their trial
NOTE Confidence: 0.7941296

00:56:48.284 --> 00:56:50.882 where baby consolidation was was utilized
NOTE Confidence: 0.7941296

00:56:50.882 --> 00:56:52.778 after atleast himself transplant

NOTE Confidence: 0.7941296
00:56:52.778 --> 00:56:55.330 with an improvement of the PFS,
NOTE Confidence: 0.7941296
00:56:55.330 --> 00:56:57.320 although with a significant there
NOTE Confidence: 0.7941296
00:56:57.320 --> 00:57:00.104 was a 33% and drop off patients
NOTE Confidence: 0.7941296
00:57:00.104 --> 00:57:02.480 that could not complete the study
NOTE Confidence: 0.7941296
00:57:02.557 --> 00:57:04.502 due to neuropathy and another
NOTE Confidence: 0.7941296
00:57:04.502 --> 00:57:07.303 study that has been done used that
NOTE Confidence: 0.7941296
00:57:07.303 --> 00:57:09.258 embolism up in this setting.
NOTE Confidence: 0.7941296
00:57:09.260 --> 00:57:11.384 It was much smaller study only
NOTE Confidence: 0.7941296
00:57:11.384 --> 00:57:13.387 with 30 patient and patient
NOTE Confidence: 0.7941296
00:57:13.387 --> 00:57:15.927 population and better risk factors.
NOTE Confidence: 0.7941296
00:57:15.930 --> 00:57:18.048 So the apotheosis behind this study
NOTE Confidence: 0.7941296
00:57:18.048 --> 00:57:20.915 is to use the these two agents
NOTE Confidence: 0.7941296
00:57:20.915 --> 00:57:23.220 in combination Vivian Evil as
NOTE Confidence: 0.7941296
00:57:23.220 --> 00:57:25.034 consolidation and utilizing only
NOTE Confidence: 0.7941296
00:57:25.034 --> 00:57:27.904 eight cycles instead of the 16 cycles
NOTE Confidence: 0.7941296

00:57:27.904 --> 00:57:30.798 that was used in the fair trial,
NOTE Confidence: 0.7941296

00:57:30.800 --> 00:57:33.278 and again, patients that were enrolled,
NOTE Confidence: 0.7941296

00:57:33.280 --> 00:57:35.716 59 patients were enrolled in this
NOTE Confidence: 0.7941296

00:57:35.716 --> 00:57:38.650 trial and they were started on that.
NOTE Confidence: 0.7941296

00:57:38.650 --> 00:57:40.710 These are the combination between
NOTE Confidence: 0.7941296

00:57:40.710 --> 00:57:41.946 evil about them,
NOTE Confidence: 0.7941296

00:57:41.950 --> 00:57:45.870 between 30 and 6075 days after a transplant.
NOTE Confidence: 0.7941296

00:57:45.870 --> 00:57:49.479 And I just want to point out that there
NOTE Confidence: 0.7941296

00:57:49.479 --> 00:57:53.311 was a lot of patients that could not
NOTE Confidence: 0.7941296

00:57:53.311 --> 00:57:57.167 complete the eight cycles that were planned.
NOTE Confidence: 0.7941296

00:57:57.170 --> 00:57:59.996 59% could not complete the treatment
NOTE Confidence: 0.7941296

00:57:59.996 --> 00:58:03.293 plan and only 76% completed 8 cycles
NOTE Confidence: 0.7941296

00:58:03.293 --> 00:58:05.648 of either brentuximab or nivolumab.
NOTE Confidence: 0.7941296

00:58:05.650 --> 00:58:08.947 So the take home message from this,
NOTE Confidence: 0.7941296

00:58:08.950 --> 00:58:11.950 that is that the treatment the
NOTE Confidence: 0.7941296

00:58:11.950 --> 00:58:14.599 maintenance after transplant is a much.

NOTE Confidence: 0.7941296

00:58:14.600 --> 00:58:16.464 It is very difficult.

NOTE Confidence: 0.7941296

00:58:16.464 --> 00:58:17.396 Treatment too,

NOTE Confidence: 0.7941296

00:58:17.400 --> 00:58:21.320 for the patients to undergo as the side

NOTE Confidence: 0.7941296

00:58:21.320 --> 00:58:23.880 effects associated with the utilization

NOTE Confidence: 0.7941296

00:58:23.880 --> 00:58:26.862 of these agents in this setting.

NOTE Confidence: 0.7941296

00:58:26.870 --> 00:58:30.006 Is associated with an increased side effects,

NOTE Confidence: 0.7941296

00:58:30.010 --> 00:58:32.435 in particular immune related adverse

NOTE Confidence: 0.7941296

00:58:32.435 --> 00:58:35.848 event that we're seeing up to 27% of

NOTE Confidence: 0.7941296

00:58:35.848 --> 00:58:38.536 the patients enrolled in this study.

NOTE Confidence: 0.7941296

00:58:38.540 --> 00:58:39.438 But nevertheless,

NOTE Confidence: 0.7941296

00:58:39.438 --> 00:58:42.132 it's very encouraging that there is

NOTE Confidence: 0.7941296

00:58:42.132 --> 00:58:45.006 a 92% progression free survival in

NOTE Confidence: 0.7941296

00:58:45.006 --> 00:58:47.970 this high risk patients for relapse

NOTE Confidence: 0.7941296

00:58:48.047 --> 00:58:50.167 even despite their prior exposure

NOTE Confidence: 0.7941296

00:58:50.167 --> 00:58:52.910 either to BB and anti PD one.

NOTE Confidence: 0.7941296

00:58:52.910 --> 00:58:56.228 And since I want to leave sometimes
NOTE Confidence: 0.7941296

00:58:56.228 --> 00:58:57.176 for question.
NOTE Confidence: 0.7941296

00:58:57.180 --> 00:58:59.616 I'm just going to mention briefly
NOTE Confidence: 0.7941296

00:58:59.616 --> 00:59:02.083 that this study think the merit
NOTE Confidence: 0.7941296

00:59:02.083 --> 00:59:04.387 of this study has been literally
NOTE Confidence: 0.7941296

00:59:04.387 --> 00:59:06.558 to enroll older patients which
NOTE Confidence: 0.7941296

00:59:06.558 --> 00:59:08.773 are under representative in most
NOTE Confidence: 0.7941296

00:59:08.773 --> 00:59:10.992 of the Hodgkin lymphoma trial.
NOTE Confidence: 0.7941296

00:59:10.992 --> 00:59:13.656 They have less prognosis and unfortunately
NOTE Confidence: 0.7941296

00:59:13.656 --> 00:59:16.319 I mean it's not a randomized trial,
NOTE Confidence: 0.7941296

00:59:16.320 --> 00:59:18.666 so patients were received either BV
NOTE Confidence: 0.7941296

00:59:18.666 --> 00:59:21.177 in monotherapy or in combination with
NOTE Confidence: 0.7941296

00:59:21.177 --> 00:59:23.793 chemotherapy and just to be very,
NOTE Confidence: 0.7941296

00:59:23.800 --> 00:59:24.648 very quick.
NOTE Confidence: 0.7941296

00:59:24.648 --> 00:59:26.768 The take home messages that
NOTE Confidence: 0.7941296

00:59:26.768 --> 00:59:28.850 DV monotherapy has been with.

NOTE Confidence: 0.7941296

00:59:28.850 --> 00:59:31.148 Very, very active, but as shown,

NOTE Confidence: 0.7941296

00:59:31.150 --> 00:59:33.060 the employer in prior studies,

NOTE Confidence: 0.7941296

00:59:33.060 --> 00:59:33.826 the PFS,

NOTE Confidence: 0.7941296

00:59:33.826 --> 00:59:35.358 was not very long,

NOTE Confidence: 0.7941296

00:59:35.360 --> 00:59:37.270 whereas when we've is combined

NOTE Confidence: 0.7941296

00:59:37.270 --> 00:59:38.034 with chemotherapy,

NOTE Confidence: 0.7941296

00:59:38.040 --> 00:59:40.338 the risks are outside effects increases,

NOTE Confidence: 0.7941296

00:59:40.340 --> 00:59:42.930 but it is associated with

NOTE Confidence: 0.7941296

00:59:42.930 --> 00:59:45.002 that much longer PFS.

NOTE Confidence: 0.7941296

00:59:45.010 --> 00:59:47.138 The only thing that they want I

NOTE Confidence: 0.7941296

00:59:47.138 --> 00:59:49.724 like is that the brand tax amount

NOTE Confidence: 0.7941296

00:59:49.724 --> 00:59:51.729 window 10 plus bendamustine armor

NOTE Confidence: 0.7941296

00:59:51.729 --> 00:59:54.023 was closed due to an excess of

NOTE Confidence: 0.7941296

00:59:54.023 --> 00:59:55.922 toxicity is not a good treatment

NOTE Confidence: 0.7941296

00:59:55.922 --> 00:59:57.286 in this elderly population.

NOTE Confidence: 0.7941296

00:59:57.290 --> 01:00:00.359 And with this I left panel open for question.

NOTE Confidence: 0.7852962

01:00:06.400 --> 01:00:08.150 Thank you all for presenting.

NOTE Confidence: 0.7852962

01:00:08.150 --> 01:00:09.900 It was really quite comprehensive.

NOTE Confidence: 0.7852962

01:00:09.900 --> 01:00:12.350 We're going to go over our allotted

NOTE Confidence: 0.7852962

01:00:12.350 --> 01:00:14.450 hour and folks can stay in.

NOTE Confidence: 0.7852962

01:00:14.450 --> 01:00:16.900 Will have a little question answer period.

NOTE Confidence: 0.7852962

01:00:16.900 --> 01:00:19.350 While we're on the topic of Hodgkin,

NOTE Confidence: 0.7852962

01:00:19.350 --> 01:00:20.750 that was really nice.

NOTE Confidence: 0.7852962

01:00:20.750 --> 01:00:21.800 Presentation documents tomorrow.

NOTE Confidence: 0.7852962

01:00:21.800 --> 01:00:23.550 How do you interpret and

NOTE Confidence: 0.7852962

01:00:23.550 --> 01:00:25.300 how do you take together?

NOTE Confidence: 0.7852962

01:00:25.300 --> 01:00:27.400 You know the five year data

NOTE Confidence: 0.7852962

01:00:27.400 --> 01:00:28.450 on the TV

NOTE Confidence: 0.7852962

01:00:28.450 --> 01:00:29.500 and first line.

NOTE Confidence: 0.78872955

01:00:30.210 --> 01:00:31.290 Incredible salvage options

NOTE Confidence: 0.78872955

01:00:31.290 --> 01:00:32.730 for patients you know.

NOTE Confidence: 0.78872955

01:00:32.730 --> 01:00:35.610 How do you put that together when you

NOTE Confidence: 0.78872955

01:00:35.610 --> 01:00:37.770 have someone that has advanced stage

NOTE Confidence: 0.78872955

01:00:37.770 --> 01:00:40.650 first line has come before you are you?

NOTE Confidence: 0.78872955

01:00:40.650 --> 01:00:43.170 You know the five year data compelling

NOTE Confidence: 0.78872955

01:00:43.170 --> 01:00:46.410 you to give more BVD or you still doing

NOTE Confidence: 0.78872955

01:00:46.410 --> 01:00:49.830 adaptive kind of raffle approach?

NOTE Confidence: 0.84333193

01:00:49.830 --> 01:00:53.134 This is this is a very good question.

NOTE Confidence: 0.84333193

01:00:53.140 --> 01:00:56.038 Interesting isn't it? It's very I mean,

NOTE Confidence: 0.84333193

01:00:56.040 --> 01:00:58.974 one of the argument against intensifying

NOTE Confidence: 0.84333193

01:00:58.974 --> 01:01:02.001 Firstline treatment is that is so well

NOTE Confidence: 0.84333193

01:01:02.001 --> 01:01:04.318 tolerated and that we have so many,

NOTE Confidence: 0.84333193

01:01:04.320 --> 01:01:07.624 I mean salvage therapy works in our chicken.

NOTE Confidence: 0.84333193

01:01:07.630 --> 01:01:11.010 So in order to improve.

NOTE Confidence: 0.84333193

01:01:11.010 --> 01:01:13.332 A small percentage of the outcome

NOTE Confidence: 0.84333193

01:01:13.332 --> 01:01:15.946 of all the patients you end up

NOTE Confidence: 0.84333193

01:01:15.946 --> 01:01:17.920 like exposing a lot of patients
NOTE Confidence: 0.84333193

01:01:17.920 --> 01:01:20.370 to a more aggressive treatment.
NOTE Confidence: 0.84333193

01:01:20.370 --> 01:01:23.352 While you could have served salvage only
NOTE Confidence: 0.84333193

01:01:23.352 --> 01:01:26.610 to those that do not respond to a DVD.
NOTE Confidence: 0.84333193

01:01:26.610 --> 01:01:29.258 So, but I think that this this five
NOTE Confidence: 0.84333193

01:01:29.258 --> 01:01:32.315 year update I really like to see that
NOTE Confidence: 0.84333193

01:01:32.315 --> 01:01:34.377 the peripheral neuropathy was not
NOTE Confidence: 0.84333193

01:01:34.377 --> 01:01:36.562 was getting better progressively year
NOTE Confidence: 0.84333193

01:01:36.562 --> 01:01:39.606 after year and there were not major
NOTE Confidence: 0.84333193

01:01:39.606 --> 01:01:41.766 sequelae regarding that approach and.
NOTE Confidence: 0.84333193

01:01:41.770 --> 01:01:44.360 I really like the fact that there
NOTE Confidence: 0.84333193

01:01:44.360 --> 01:01:47.499 was no not not an increase of
NOTE Confidence: 0.84333193

01:01:47.499 --> 01:01:51.950 secondary malignancy or of. The.
NOTE Confidence: 0.84333193

01:01:51.950 --> 01:01:53.900 Any bad outcome on pregnancies,
NOTE Confidence: 0.84333193

01:01:53.900 --> 01:01:57.104 but what I really think is the value of
NOTE Confidence: 0.84333193

01:01:57.104 --> 01:02:00.023 this approach as compared to PET adopted

NOTE Confidence: 0.84333193

01:02:00.023 --> 01:02:03.617 one is that you don't need to adopt it.

NOTE Confidence: 0.84333193

01:02:03.620 --> 01:02:06.357 The PFS of patients that have a

NOTE Confidence: 0.84333193

01:02:06.357 --> 01:02:08.802 pet positive after 2 cycle is very

NOTE Confidence: 0.84333193

01:02:08.802 --> 01:02:12.055 good and is as good as the one that

NOTE Confidence: 0.84333193

01:02:12.055 --> 01:02:14.365 you get using escalated beacopp

NOTE Confidence: 0.84333193

01:02:14.365 --> 01:02:16.790 and especially population.

NOTE Confidence: 0.84333193

01:02:16.790 --> 01:02:17.140 That's

NOTE Confidence: 0.80653936

01:02:17.140 --> 01:02:19.550 a really nice summary and I have

NOTE Confidence: 0.80653936

01:02:19.550 --> 01:02:21.276 very similar feelings of that,

NOTE Confidence: 0.80653936

01:02:21.276 --> 01:02:22.660 so it's a complicated

NOTE Confidence: 0.80653936

01:02:22.660 --> 01:02:23.695 conversation that certainly

NOTE Confidence: 0.80653936

01:02:23.695 --> 01:02:25.420 patients should be presented both.

NOTE Confidence: 0.80653936

01:02:25.420 --> 01:02:27.139 Kind of adaptive Anet DVD

NOTE Confidence: 0.80653936

01:02:27.140 --> 01:02:28.520 and tailored to patient

NOTE Confidence: 0.80653936

01:02:28.520 --> 01:02:30.590 preferences and kind of a profile.

NOTE Confidence: 0.80653936

01:02:30.590 --> 01:02:33.005 Not surprisingly, there are a number of
NOTE Confidence: 0.80653936

01:02:33.010 --> 01:02:35.080 questions about CNS prophylaxis of Doctor
NOTE Confidence: 0.80653936

01:02:35.080 --> 01:02:36.109 Kothari can step
NOTE Confidence: 0.80653936

01:02:36.110 --> 01:02:38.870 up to the plate, but you know how?
NOTE Confidence: 0.80653936

01:02:38.870 --> 01:02:40.600 How do you interpret the
NOTE Confidence: 0.80653936

01:02:40.600 --> 01:02:42.664 two abstracts that were presented oral
NOTE Confidence: 0.80653936

01:02:42.664 --> 01:02:45.769 session? I know there was a lot of kind
NOTE Confidence: 0.80653936

01:02:45.770 --> 01:02:47.730 of discussion during that meeting.
NOTE Confidence: 0.80653936

01:02:47.730 --> 01:02:49.650 Has that informed how you
NOTE Confidence: 0.80653936

01:02:49.650 --> 01:02:51.110 approach patients that are
NOTE Confidence: 0.8181126

01:02:51.110 --> 01:02:52.930 high risk for sinas that
NOTE Confidence: 0.8181126

01:02:52.930 --> 01:02:55.120 relapse? I think both abstracts kind
NOTE Confidence: 0.8181126

01:02:55.120 --> 01:02:57.675 of confused us further. To be honest.
NOTE Confidence: 0.8181126

01:02:57.675 --> 01:03:00.230 I mean it's great set of data,
NOTE Confidence: 0.8181126

01:03:00.230 --> 01:03:03.118 especially the second set of data that I
NOTE Confidence: 0.8181126

01:03:03.118 --> 01:03:05.710 presented which is a multi institutional US.

NOTE Confidence: 0.8181126

01:03:05.710 --> 01:03:08.265 You know study where there are more

NOTE Confidence: 0.8181126

01:03:08.265 --> 01:03:10.224 than thousand patients so you know

NOTE Confidence: 0.8181126

01:03:10.224 --> 01:03:12.796 the the end was pretty good to have

NOTE Confidence: 0.8181126

01:03:12.796 --> 01:03:15.651 meaningful interpretation, but I think.

NOTE Confidence: 0.8181126

01:03:15.651 --> 01:03:18.753 Overall, I think my summary of,

NOTE Confidence: 0.8181126

01:03:18.760 --> 01:03:21.210 I think both both abstracts

NOTE Confidence: 0.8181126

01:03:21.210 --> 01:03:24.160 would be that we need better,

NOTE Confidence: 0.8181126

01:03:24.160 --> 01:03:26.340 stronger frontline regiments to

NOTE Confidence: 0.8181126

01:03:26.340 --> 01:03:30.129 eradicate the real high risk DCL from

NOTE Confidence: 0.8181126

01:03:30.129 --> 01:03:32.685 the get go because that eventually

NOTE Confidence: 0.8181126

01:03:32.685 --> 01:03:35.983 leads to a CNS relapse and that

NOTE Confidence: 0.8181126

01:03:35.983 --> 01:03:38.398 was shown through the Alberta,

NOTE Confidence: 0.8181126

01:03:38.400 --> 01:03:40.855 Canada study where patients who

NOTE Confidence: 0.8181126

01:03:40.855 --> 01:03:42.819 got intensive chemo immunotherapy.

NOTE Confidence: 0.8181126

01:03:42.820 --> 01:03:45.830 The trend was towards better

NOTE Confidence: 0.8181126

01:03:45.830 --> 01:03:47.636 CNS relapse rates.
NOTE Confidence: 0.8181126

01:03:47.640 --> 01:03:50.192 And I guess the same could be told
NOTE Confidence: 0.8181126

01:03:50.192 --> 01:03:53.134 even you know the fact that autologous
NOTE Confidence: 0.8181126

01:03:53.134 --> 01:03:55.303 stem cell transplant was helpful.
NOTE Confidence: 0.8181126

01:03:55.303 --> 01:03:56.069 So overall,
NOTE Confidence: 0.8181126

01:03:56.070 --> 01:03:58.520 I would say that this these abstracts
NOTE Confidence: 0.8181126

01:03:58.520 --> 01:04:00.725 don't change my practice of using
NOTE Confidence: 0.8181126

01:04:00.725 --> 01:04:02.540 high dose methotrexate with R
NOTE Confidence: 0.8181126

01:04:02.540 --> 01:04:05.022 CHOP or most likely into fecal
NOTE Confidence: 0.8181126

01:04:05.022 --> 01:04:06.710 methotrexate with those adjusted
NOTE Confidence: 0.8181126

01:04:06.710 --> 01:04:09.092 epoch in high risk blpi atients.
NOTE Confidence: 0.8181126

01:04:09.092 --> 01:04:11.390 What I would say I think,
NOTE Confidence: 0.8181126

01:04:11.390 --> 01:04:13.300 which was interesting to note,
NOTE Confidence: 0.8181126

01:04:13.300 --> 01:04:14.828 is the liver involvement
NOTE Confidence: 0.8181126

01:04:14.828 --> 01:04:15.974 and testicular involvement,
NOTE Confidence: 0.8181126

01:04:15.980 --> 01:04:17.572 which we traditionally don't.

NOTE Confidence: 0.8181126

01:04:17.572 --> 01:04:19.562 Think of it that way,

NOTE Confidence: 0.8181126

01:04:19.570 --> 01:04:21.098 although there are some

NOTE Confidence: 0.8181126

01:04:21.098 --> 01:04:22.626 scattered papers about it,

NOTE Confidence: 0.8181126

01:04:22.630 --> 01:04:25.241 I think this is just to highlight

NOTE Confidence: 0.8181126

01:04:25.241 --> 01:04:27.606 that you know liver and testicle

NOTE Confidence: 0.8181126

01:04:27.606 --> 01:04:28.758 involvement also portends

NOTE Confidence: 0.8181126

01:04:28.758 --> 01:04:31.980 higher CNS relapse rate.

NOTE Confidence: 0.8181126

01:04:31.980 --> 01:04:32.380 Thank

NOTE Confidence: 0.82776004

01:04:32.380 --> 01:04:35.194 you for that and then Doctor Safi.

NOTE Confidence: 0.82776004

01:04:35.200 --> 01:04:37.622 Really, I think lots of exciting

NOTE Confidence: 0.82776004

01:04:37.622 --> 01:04:40.042 early phase studies in T cell.

NOTE Confidence: 0.82776004

01:04:40.042 --> 01:04:43.260 But certainly I think we need kind of

NOTE Confidence: 0.82776004

01:04:43.260 --> 01:04:44.469 larger randomized prospective

NOTE Confidence: 0.82776004

01:04:44.470 --> 01:04:47.284 data and basically everyone with T cell

NOTE Confidence: 0.82776004

01:04:47.290 --> 01:04:48.906 lymphoma should be on

NOTE Confidence: 0.82776004

01:04:48.906 --> 01:04:50.520 protocol, right? If we're
NOTE Confidence: 0.82776004

01:04:50.520 --> 01:04:51.729 going to really
NOTE Confidence: 0.82776004

01:04:51.730 --> 01:04:52.939 start improving the
NOTE Confidence: 0.82776004

01:04:52.940 --> 01:04:54.950 outcomes, can you talk about
NOTE Confidence: 0.82776004

01:04:54.950 --> 01:04:56.159 some of the
NOTE Confidence: 0.82776004

01:04:56.160 --> 01:04:59.380 trials that we have open in T cell
NOTE Confidence: 0.82776004

01:04:59.380 --> 01:05:01.510 lymphoma either currently or in
NOTE Confidence: 0.82776004

01:05:01.510 --> 01:05:03.850 the future that? We hope to kind
NOTE Confidence: 0.8472827

01:05:03.850 --> 01:05:05.120 of increase our accruals for.
NOTE Confidence: 0.7535696

01:05:06.930 --> 01:05:09.080 Yes, absolutely. Actually we have.
NOTE Confidence: 0.7535696

01:05:09.080 --> 01:05:11.978 We do have a few exciting things
NOTE Confidence: 0.7535696

01:05:11.978 --> 01:05:15.298 coming down the Pike so we do use
NOTE Confidence: 0.7535696

01:05:15.298 --> 01:05:18.293 those adjusted epoch quite a bit for
NOTE Confidence: 0.7535696

01:05:18.293 --> 01:05:21.513 aggressive T cell lymphoma here at Yale.
NOTE Confidence: 0.7535696

01:05:21.520 --> 01:05:24.630 And so we have an IIT that is in the
NOTE Confidence: 0.7535696

01:05:24.720 --> 01:05:28.171 works which is which is funded and

NOTE Confidence: 0.7535696

01:05:28.171 --> 01:05:31.378 basically the protocol is being developed.

NOTE Confidence: 0.7535696

01:05:31.380 --> 01:05:33.740 And that's with those suggested

NOTE Confidence: 0.7535696

01:05:33.740 --> 01:05:36.100 epoch with mogamulizumab as frontline

NOTE Confidence: 0.7535696

01:05:36.168 --> 01:05:38.218 therapy in these patients and.

NOTE Confidence: 0.7535696

01:05:38.220 --> 01:05:41.300 So epoch does have overall, you know,

NOTE Confidence: 0.7535696

01:05:41.300 --> 01:05:43.475 looking at the chop response

NOTE Confidence: 0.7535696

01:05:43.475 --> 01:05:46.204 rates of like 3540% CR rates,

NOTE Confidence: 0.7535696

01:05:46.204 --> 01:05:49.403 epoch does tend to have a better

NOTE Confidence: 0.7535696

01:05:49.403 --> 01:05:52.422 overall response rate in CR rates in

NOTE Confidence: 0.7535696

01:05:52.422 --> 01:05:55.460 the 60% think you know 60% range.

NOTE Confidence: 0.7535696

01:05:55.460 --> 01:05:59.880 So the idea is really to try to get this.

NOTE Confidence: 0.7535696

01:05:59.880 --> 01:06:02.270 These patients and the deepest

NOTE Confidence: 0.7535696

01:06:02.270 --> 01:06:05.644 remission that you can and you know

NOTE Confidence: 0.7535696

01:06:05.644 --> 01:06:08.773 then then take them to transplants and.

NOTE Confidence: 0.7535696

01:06:08.780 --> 01:06:11.130 It's really an excited study.

NOTE Confidence: 0.7535696

01:06:11.130 --> 01:06:14.890 It is a phase two single arm study,
NOTE Confidence: 0.7535696

01:06:14.890 --> 01:06:18.096 but I think it's a novel combination
NOTE Confidence: 0.7535696

01:06:18.096 --> 01:06:20.060 that we're excited about.
NOTE Confidence: 0.7535696

01:06:20.060 --> 01:06:23.268 As far as the and one additional study
NOTE Confidence: 0.7535696

01:06:23.268 --> 01:06:26.552 would be in CD 30 positive patients
NOTE Confidence: 0.7535696

01:06:26.552 --> 01:06:29.545 looking at the combination of rituximab
NOTE Confidence: 0.7535696

01:06:29.545 --> 01:06:32.105 with pembrolizumab and that's kind
NOTE Confidence: 0.7535696

01:06:32.105 --> 01:06:36.092 of an idea that I wrote at Vanderbilt
NOTE Confidence: 0.7535696

01:06:36.092 --> 01:06:39.500 and Vanderbilt that we're hoping to open.
NOTE Confidence: 0.7535696

01:06:39.500 --> 01:06:42.350 In the coming months as well.
NOTE Confidence: 0.7535696

01:06:42.350 --> 01:06:45.438 As far as the present studies are concerned,
NOTE Confidence: 0.7535696

01:06:45.440 --> 01:06:48.528 the ones that we are still enrolling on,
NOTE Confidence: 0.7535696

01:06:48.530 --> 01:06:51.225 we have a couple of oral agents,
NOTE Confidence: 0.7535696

01:06:51.230 --> 01:06:52.774 including the DIETY study,
NOTE Confidence: 0.7535696

01:06:52.774 --> 01:06:55.090 which is basically an IDH one,
NOTE Confidence: 0.7535696

01:06:55.090 --> 01:06:56.521 IDH, two inhibitor.

NOTE Confidence: 0.7535696

01:06:56.521 --> 01:06:58.906 And it has to be.

NOTE Confidence: 0.7535696

01:06:58.910 --> 01:07:00.418 It has, you know,

NOTE Confidence: 0.7535696

01:07:00.418 --> 01:07:02.303 single agent activity in relapsed

NOTE Confidence: 0.7535696

01:07:02.303 --> 01:07:03.718 refractory T cell lymphoma,

NOTE Confidence: 0.7535696

01:07:03.720 --> 01:07:05.200 and definitely something that

NOTE Confidence: 0.7535696

01:07:05.200 --> 01:07:06.680 we've seen responses with,

NOTE Confidence: 0.7535696

01:07:06.680 --> 01:07:08.732 and sometimes it's just the right

NOTE Confidence: 0.7535696

01:07:08.732 --> 01:07:10.991 treatment to try to get these

NOTE Confidence: 0.7535696

01:07:10.991 --> 01:07:12.230 patients in remission,

NOTE Confidence: 0.7535696

01:07:12.230 --> 01:07:14.080 take take them to transplant.

NOTE Confidence: 0.839506

01:07:16.460 --> 01:07:19.228 Thank you so much and this was great.

NOTE Confidence: 0.839506

01:07:19.230 --> 01:07:20.955 Amazing talks and thanks God

NOTE Confidence: 0.839506

01:07:20.955 --> 01:07:22.335 for this the moderation.

NOTE Confidence: 0.839506

01:07:22.340 --> 01:07:24.418 The questions as you heard a

NOTE Confidence: 0.839506

01:07:24.420 --> 01:07:25.804 lot of exciting developments

NOTE Confidence: 0.839506

01:07:25.804 --> 01:07:27.880 going on in the informal work.
NOTE Confidence: 0.839506

01:07:27.880 --> 01:07:29.950 We have a lot of actually
NOTE Confidence: 0.839506

01:07:29.950 --> 01:07:30.985 active clinical trials,
NOTE Confidence: 0.839506

01:07:30.990 --> 01:07:33.318 so feel free to reach out to any
NOTE Confidence: 0.839506

01:07:33.318 --> 01:07:35.077 further Informa experts or any
NOTE Confidence: 0.839506

01:07:35.077 --> 01:07:36.927 questions about your patience or
NOTE Confidence: 0.839506

01:07:36.927 --> 01:07:38.950 any referrals for clinical trials.
NOTE Confidence: 0.839506

01:07:38.950 --> 01:07:41.116 Reminder that a recording of this
NOTE Confidence: 0.839506

01:07:41.116 --> 01:07:42.923 session will be available next
NOTE Confidence: 0.839506

01:07:42.923 --> 01:07:45.023 week and along with the slides and
NOTE Confidence: 0.839506

01:07:45.023 --> 01:07:46.968 should be an enduring material.
NOTE Confidence: 0.839506

01:07:46.970 --> 01:07:48.070 For your future reference,
NOTE Confidence: 0.839506

01:07:48.070 --> 01:07:50.050 next week will have the by Lloyd
NOTE Confidence: 0.839506

01:07:50.050 --> 01:07:51.700 updates and thank you so much
NOTE Confidence: 0.839506

01:07:51.700 --> 01:07:53.410 everyone and have a great weekend.
NOTE Confidence: 0.839506

01:07:53.410 --> 01:07:53.970 Thank you.